Hofburg Conference Center, Vienna, Austria · MOBILE APPLICATION Get all information you need at...

7th Annual Meeting of the International Cytokine & Interferon Society

Hofburg Conference Center, Vienna, Austria

20 - 23 October 2019

www.vienna.cytokinesociety.org

World-Class Quality | Superior Customer Support | Outstanding Value

LEGENDplex™One Assay, Multiple Analytes.

Toll-Free Tel (US & Canada): 1.877.BIOLEGEND (246.5343)Tel: 858.768.5800

biolegend.com

08-0075-12

BioLegend is ISO 13485:2016 Certi�ed

Quantifying multiple biomarkers should be easy.

LEGENDplex™ multiplex panels reliably and accurately generate more data, in less time, with just one assay.

• Speci�cally designed for use with standard �ow cytometers

• Free data analysis software included with every assay

• Human, mouse, rat, and non-human primate speci�cities

• Expanding list of analyte targets

• Flexible ordering formats

Visit: biolegend.com/legendplex

3

Table of Contents

Welcome Message 04

Committee Members 04

General Information 07

Networking Events 08

Program Overview 10 - 12

Scientific Program 13 - 23

Sunday 20 October 13

Monday 21 October 14 - 16

Tuesday 22 October 17 - 19

Wednesday 23 October 20 - 23

Posters 26 - 39

Award Winners 32

Company Profiles 41 - 45

Layout of Venue & Exhibition Area 47

Acknowledgements 48

Poster Session 1: Monday 21 October 26 - 31

Poster Session 2: Tuesday 22 October 34 - 39

Sunday 20 October 10

Monday 21 October 10

Tuesday 22 October 11

Wednesday 23 October 12

List of Invited Speakers 06

4

Welcome Message

Committee Members

SCIENTIFIC ORGANIZING COMMITTEE SCIENTIFIC ADVISORY BOARD

Georg SchettUniversity of Erlangen-Nuremberg

Germany

Leo JoostenUniversity of Nijmegen

The Netherlands

Mariana J. KaplanNational Institute of Arthritis, Musculoskeletal

and Skin DiseasesUSA

Stefan Rose-JohnUniversity of Kiel

Germany

Yoshiya TanakaUniversity of Occupational and Environmental Health,

Kitakyushu-shi, Fukuoka, Japan

Thomas Decker (AT)

Kate Fitzgerald (US)

Richard Flavell (US)

Cem Gabay (CH)

Sarah Gaffen (US)

Brendan Jenkins (AU)

Simon Jones (UK)

Anne O’Garra (UK)

Nancy Reich (US)

Josef Schwarzmeier (AT)

Akinori Takaoka (JP)

Kazuhiko Yamamoto (JP)

Dear Colleagues,

We would like to welcome you to the 7th Annual Meeting of the International Cytokine & Interferon Society (ICIS) in Vienna.

The ICIS annual meeting has become the world’s most important annual conference on basic, clinical and translational research on cytokines and their roles in host defense, infl ammation, tissue repair and cancer.

Cytokine targeting is one of the greatest revolutions in modern medicine. A large number of severe and sometimes even lethal infl ammatory and autoimmune diseases have become manageable due to selective inhibition of cytokines and cytokine signaling. The development of compounds that selectively inhibit cytokines or interferons has permitted an so far unprecedented molecular characterization of human disease. Cytokines also contribute to cancer development and alterations in tissue homeostasis. Cytokines 2019 addresses these developments and provides a comprehensive picture of the current knowledge of cytokine pathways in human disease and the strategies to inhibit, modulate or foster cytokine responses.

We believe this will be a fantastic meeting in the beautiful city of Vienna with many networking opportunities and hope that you make the most of the opportunities it provides.

We wish you a successful meeting!

Georg SchettChairman of Cytokines 2019

www.ayoxxa.com

www.vierviertel.com

Where are your limits? Multiplex insights from as little as 3 µL sample

3μl

FIND OUT MORE

Visit us at booth #11 to discussyour research needs

6

List of Invited SpeakersStuart Allan

University of Manchester, UK

Francesca BaroneQueen Elisabeth Hospital, UK

Burkhard BecherUniversity of Zurich, CH

Andreas BergthalerCeMM Research Center for Molecular Medicine, AT

Aline BozecUniversity of Erlangen-Nuremberg, DE

Gordon BrownUniversity of Exeter, UK

Chris BuckleyQueen Elisabeth Hospital, UK

Jane BucknerBenaroya Research Institute, US

Tom CupedoErasmus University Medical Center, NL

Thomas Decker, Keynote SpeakerUniversity of Vienna, AT

Chen Dong, BioLegend William E. Paul AwardTsinghua University, CN

Dirk ElewautGhent University, BE

Cem GabayUniversity Hospitals of Geneva, CH

Sarah GaffenUniversity of Pittsburgh, US

Raphaela Goldbach ManskyNIAID/DIR, US

Romina GoldszmidNIH, US

Johann GudjonssonUniversity of Michigan, US

Lucie HeinzerlingUniversity of Erlangen-Nuremberg, DE

John IsaacsNewcastle University, UK

Shintaro IwamaNagoya University Hospital, JP

Akiko Iwasaki, Milstein AwardYale University, US

Brendan JenkinsMonash Institute of Medical Research, AU

Simon JonesCardiff University, UK

Kenji KabashimaKyoto University, JP

Yuko KanekoKeio University, JP

Thomas KornTechnical University of Munich, DE

Michaela KressMedical University of Innsbruck, AT

Gerhard KrönkeUniversity of Erlangen-Nuremberg, DE

Atushi KumanogoOsaka University, JP

Ed LavelleTrinity College Dublin, IE

Lydia Lynch, Keynote SpeakerTrinity College Dublin, IE

Tracy L.McGahaPrincess Margaret Cancer Centre, CA

Anne O’GarraThe Francis Crick Institute, UK

Taku OkazakiUniversity of Tokushima, JP

Andreas RammingUniversity of Erlangen-Nuremberg, DE

Nancy ReichStony Brook University, US

Stefan Rose-JohnUniversity of Kiel, DE

Anna RubartelliHospital San Martino, IT

Georg SchettUniversity of Erlangen-Nuremberg, DE

Brigitta StockingerThe Francis Crick Institute, UK

Tsutomu TakeuchiKeio University, JP

Peter TaylorUniversity of Oxford, UK

Diamant ThaciUniversity of Schleswig-Holstein, DE

Irina UdalovaUniversity of Oxford, UK

David VoehringerUniversity of Erlangen-Nuremberg, DE

Erwin WagnerMedical University of Vienna, AT

Sarah WalmsleyUniversity of Edinburgh, UK

Ari WaismanUniversity of Mainz, DE

Cornelia WeyandStanford University, US

Hao Wu, Milstein AwardHarvard University, US

7

MEETING VENUE AND LOCATIONHofburg Conference CenterHeldenplatz, 1010 Vienna, Austria

MEETING ORGANIZERMCI Suisse SA has been selected by ICIS as the offi cial meeting organizer to process registrations, abstract management, exhibition and sponsorship. All correspondence should be sent to:

Cytokines 2019 c/o MCI Suisse SA9 Rue de Pré-Bouvier1242 Satigny, Geneva, SwitzerlandE-mail: [email protected]

ICIS HEADQUARTERSJoan Oefner, Managing DirectorInternational Cytokine & Interferon Society

297 Kinderkamack Road, Suite 348Oradell, NJ 07649, USATel: +1 800 947 19 60 / +49 171 104 91 81Fax: +1 201 322 18 18E-mail: [email protected]

MEETING DOCUMENTS AND BADGESMeeting documents should be collected on-site at the registration desk at the Hofburg Conference Center. Name badges must be worn visibly all times during the meeting and in the exhibition area.

MOBILE APPLICATIONGet all information you need at your fi ngertips with the Cytokines 2019 Mobile Application. It is available for free on iOS and Android.

CELLULAR PHONES AND PAGERSAs a courtesy to all meeting attendees and speakers, cellular phones and other electronic devices must be operated in silent or vibration mode during sessions. No cellular phone conversations are permitted during sessions. Picture taking, fi lming or recording of the sessions is forbidden.

CERTIFICATE OF ATTENDANCEA certifi cate of attendance will be sent by email after the meeting to all duly registered participants who attended the meeting.

FOOD AND BEVERAGEComplimentary coffee and tea are served in the exhibition during offi cial coffee breaks. Lunch will be provided to the attendees of the lunchtime sessions only. For other delegates, there are several restaurants within walking distance of the Hofburg Conference Center. Please check the meeting app for details and directions.

INTERNETFree wireless internet access is available in the meeting spaces. WiFi Name: HofburgSecuredPassword: Cytokines19

OFFICIAL LANGUAGEThe offi cial meeting language is English. No simultaneous interpretation will be available.

SMOKING POLICYThe meeting venue is entirely non-smoking.

SURVEY/MEETING EVALUATIONWe would be grateful if you can take a few minutes to answer an online survey that will be sent to you shortly after the meeting. Your valuable feedback will help us to improve the organization and quality of future Cytokines meetings.

REGISTRATION DESK OPENING HOURSSunday 20 October 15:00 - 20:30Monday 21 October 08:00 - 17:30Tuesday 22 October 08:00 - 17:30Wednesday 23 October 08:00 - 15:00

EXHIBITION OPENING HOURSSunday 20 October 16:00 - 20:30Monday 21 October 10:00 - 16:00Tuesday 22 October 10:00 - 16:00Wednesday 23 October 10:00 - 14:00

SPEAKERS’ PREVIEW ROOM OPENING HOURSSunday 20 October 15:00 - 18:00Monday 21 October 08:00 - 17:30Tuesday 22 October 08:00 - 17:30Wednesday 23 October 08:00 - 15:00

TRAVEL INSURANCEIt is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. Cytokines 2019 and MCI Suisse S.A. as organizers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the delegates and accompanying persons.

WEBSITEwww.vienna.cytokinesociety.org

General Information

8

Networking Events

SUNDAY 20 OCTOBER19:25 - 20:30 - Welcome Reception - Hofburg Conference Center

The scientifi c organizing committee is pleased to welcome all participants and registered accompanying persons to renew connections and meet new colleagues.

Due to the central location of the Hofburg venue in the heart of Vienna, participants are encouraged to visit some of the nearby restaurants together in groups following the welcome reception. Please use the meeting app for more information.

TUESDAY 22 OCTOBER19:15 - 23:00 - Networking Dinner - Rathaus, City Town Hall

The offi cial meeting networking evening is a great opportunity for delegates to exchange and share knowledge in a more informal setting. The evening will be accompanied with music from the band Grossmütterchen Hatz & Klok, providing the perfect setting for the dance fl oor.

This will be a standing dinner to motivate networking and not a standard sit-down gala dinner.

Delegates who wish to attend this networking opportunity need to reserve for their ticket, in advance. For those that have not reserved a ticket please check a the registration desk as soon as possible for availability of additional tickets, which are at a price of € 50 for participants and € 25 for trainees.

The venue is provided with the kind support of the Vienna Mayor’s offi ce.

GROSSMÜTTERCHEN HATZ & KLOK

The GROSSMÜTTERCHEN (means “Grandma”) HATZ & KLOK is a humorous “Worldjazzfolkskapop-Quintet”. Their infl uences are drawn from Klezmer, Balkan Folk, Latin American and from classical music. Their debut album “Gallato” was presented at the International Klezmore-Festival 2011.

Since spring 2016 they tour with a new 5 piece line up. Combine virtuouso musicians who have played with Randy Brecker, Dean Bowman and for Shantels Bucovina Club Orkestar or the Sandy Lopicic Orkestar amongst others, dance tunes and passion for playing … the audience loves this “cocktail”.

Rathaus

Hofburg Conference Center

C ining Caring with Research r a etter i e

s s ss s

s s´s s s ss

s, s

M www.lilly.at

10

WELCOME RECEPTION & OPENING OF THE EXHIBITION

Program Overview

MONDAY 21 OCTOBER

SUNDAY 20 OCTOBER

17:00 - 19:25

FESTSAAL

OPENING CEREMONYPresident’s LectureAwards Ceremony

2019 Milstein Award Winner LecturesKeynote Lecture

19:25 - 20:30

POSTER & EXHIBIT AREA

POSTER SESSION 1

ORAL ABSTRACT SESSION 1with a focus on cytokine signaling

Presentations with lunch

ORAL ABSTRACT SESSION 2with a focus on T cellsPresentations with lunch

BREAK

09:00 - 10:40

10:40 - 11:10

PARALLEL SESSION 2Sponsored by AstraZeneca

Biology and targeting of type 2-mediated immune responses

11:10 - 12:55

13:15 - 14:15

12:45 - 14:15

14:15 - 15:50

16:00 - 17:35

PLENARY SESSION 1Sponsored by BioLegend & Regeneron

Mechanisms and treatment of skin inflammation: The IL-23/IL-17 pathway

COFFEE BREAK & VISIT THE EXHIBITION

FESTSAAL


FESTSAAL ZEREMONIENSAAL

PARALLEL SESSION 3Sponsored by Nektar Therapeutics

Induction of immune tolerance – fact or fiction?


POSTER AREA


PARALLEL SESSION 4Sponsored by Janssen

Regulation of autoimmunity and autoimmune disease by cytokines

PARALLEL SESSION 5Sponsored by Pfizer

Cytokine biology meets the gut: Intestinal inflammation

11

NETWORKING DINNER AT THE VIENNA TOWN HALL

Program Overview

TUESDAY 22 OCTOBER

POSTER SESSION 2

ORAL ABSTRACT SESSION 3with a focus on viral responses


ORAL ABSTRACT SESSION 4 with a focus on tumor responses


BREAK

09:00 - 10:35

10:35 - 11:05

PARALLEL SESSION 7Supported in part by an unrestricted

educational grant from Cytokine JournalImmune metabolism regulating cytokine production and immune cell polarization

11:05 - 12:40

13:10 - 14:10

12:40 - 14:10

14:10 - 15:40

15:50 - 17:25

PLENARY SESSION 2Sponsored by the Japanese Society of Interferon & Cytokine Research

Cytokine-related diseases after checkpoint inhibition


FESTSAAL



PARALLEL SESSION 8Sponsored by Eli Lilly and Company

Therapeutic targeting of the cytokine signaling pathways


POSTER AREA


PARALLEL SESSION 9Targeting neutrophils and macrophages

in immune-mediated disease

PARALLEL SESSION 10Orchestration of

inflammatory responses by IL-6

ICIS MEMBERS MEETING AND DISTRIBUTION OF TRAVEL AWARDS17:25 - 18:10

FESTSAAL

19:15 - 23:00

OFFSITE

12

PLENARY SESSION 3The Mary Ann Liebert, Inc./Journal of Interferon and Cytokine Research Symposium

in Honor of Philip I. Marcus:Pattern recognition receptors in immunity and disease

Program Overview

WEDNESDAY 23 OCTOBER

CLOSING & INVITATION TO CYTOKINES 2020 IN SEATTLE

BREAK

PARALLEL SESSION 13Sponsored by Novartis

Cytokine-mediated resident tissue destruction and fibrotic responses

PARALLEL SESSION 14Local and systemic effects of

IL-1 family cytokines in disease


PARALLEL SESSION 11Sponsored by Bristol-Myers Squibb

Type I interferons: Biology and their role in disease

09:00 - 10:45

11:05 - 12:50

10:45 - 11:05

12:50 - 14:00

13:00 - 14:00


PARALLEL SESSION 12Sponsored by Chugai Pharmaceutical

Novel aspects of IL-6 inhibition in disease




ORAL ABSTRACT SESSION 5with a focus on infection biology


ORAL ABSTRACT SESSION 6with a focus on STING pathway


14:00 - 15:35

FESTSAAL

15:35

FESTSAAL

13

Opening Remarks: Georg Schett (DE)

Scientifi c Program - Sunday 20 October

17:05 - 17:10Introduction: Nancy Reich (US)

17:05 - 17:35BioLegend William E. Paul Award: Chen Dong (CN) presented by Jie Zhou (US)

Honorary Lifetime Membership Award: Kouji Matsushima (JP)

Milstein Awards: Akiko Iwasaki (US) & Hao Wu (US)

Distinguished Services Award: Bryan Williams (AU)

Milstein Young Investigator Awards: Juan Luis Mendoza (US), Juan Fuxman Bass (US), Sarah Doyle (IE), Yuxin Wang (US), Ryan A. Langlois (US)

The Christina Fleischmann Award to Young Women Investigator: Meike Dittmann (US)

The Sidney Pestka Graduate Award & Post Graduate Award: Billur Akkaya (US), Anukriti Mathur (AU), presented by Robert Pestka (US)

17:35 - 18:05Milstein Award Lecture 1: Role of interferons in antiviral response: Akiko Iwasaki (US)

18:05 - 18:35Milstein Award Lecture 2: Infl ammasomes in health and disease: Hao Wu (US)

18:35 - 18:45Milstein Young Investigator Award Winner: O001A - Structure of the interferon gamma receptor complex reveals a mechanism for decoupling pleiotropy: J. L. Mendoza (US)* - N. K. Escalante - K. M. Jude - J. Sotolongo Bellon - L. Su - T. M. Horton - N. Tsutsumi - S. J. Berardinelli - R. S. Haltiwanger - J. Piehler - E. G. Engleman - K. C. Garcia

Presentation of the 2019 Milstein Awards, the 2019 BioLegend William E. Paul Award, ICIS Distinguished Services Award, the ICIS Honorary Lifetime Membership Award and the 2019 Young Investigator AwardsBryan Williams (AU) & Kate Fitzgerald (US)

17:05 - 17:35AWARDS CEREMONY

FESTSAAL

17:00 - 17:05OPENING CEREMONY

FESTSAAL

17:35 - 18:452019 MILSTEIN AWARD WINNER LECTURES

FESTSAAL

Fueling the fi restarters: Lydia Lynch (IE)

18:45 - 19:25KEYNOTE LECTURE 1

FESTSAAL

19:25 - 20:30WELCOME RECEPTION & OPENING OF THE EXHIBITS

EXHIBIT AREA

14

Scientifi c Program - Monday 21 October

11:10 - 11:35Induction of immune tolerance – fact or fi ction?: John Isaacs (UK)

11:35 - 12:00Induction of immune tolerance in autoimmunity - what is standing in our way?: Jane H. Buckner (US)

12:00 - 12:25Environmental sensors, innate immune regulation, and tolerance to self: Tracy L. McGaha (CA)

12:25 - 12:35O003 - Engineering IL-10 super-agonists to boost IL-10 anti-infl ammatory responses: I. M. Gonzalez (UK)* - C. Gorby - J. Sotolongo - J. Piehler

12:35 - 12:45 O004 - Targeting IFN activity to dendritic cells for in vivo tolerization and protection against EAE:A. Cauwels (BE)* - S. Van Lint - D. Catteeuw - E. Rogge - A. Verhee - S. Pang - M. Prinz - G. Uze - J. Tavernier

12:45 - 12:55Milstein Young Investigator Award Winner: O004B - Mapping of the human cytokine gene regulatory network: J. F. Bass (US)* - C. Santoso - S. Carrasco Pro - A. Dafonte Imedio - K. A. Gan - J. A. Sewell - M. Martinez - R. Sereda - S. Mehta - A. Luis - A. Henderson

Sponsored by Nektar TherapeuticsAri Waismann (DE) & Akiko Iwasaki (JP)

11:10 - 12:55PARALLEL SESSION 3: INDUCTION OF IMMUNE TOLERANCE - FACT OR FICTION?

ZEREMONIENSAAL

09:00 - 09:25BioLegend William E. Paul Award for Excellence in Cytokine Research Award Winner: Molecular mechanisms in IL-17A-driven psoriatic infl ammation: Chen Dong (CN)

09:25 - 09:50Inhibition of IL-17 and IL 23 as a treatment target in psoriasis: Diamant Thaci (DE)

09:50 - 10:15A tale of two cytokines: IL-17 and IL-22 in fungal host defense: Sarah Gaffen (US)

10:15 - 10:40IL-17 controls CNS autoimmunity through the intestinal microbiome: Ari Waisman (DE)

Sponsored by BioLegend & RegeneronGeorg Schett (DE) & Sarah Gaffen (US)

09:00 - 10:40PLENARY SESSION 1: MECHANISMS AND TREATMENT OF SKIN INFLAMMATION: THE IL-23/IL-17 PATHWAY

FESTSAAL

Sponsored by AstraZenecaHiroki Yoshida (JP) & Andreas Ramming (DE)

11:10 - 12:45PARALLEL SESSION 2: BIOLOGY AND TARGETING OF TYPE 2-MEDIATED IMMUNE RESPONSES

FESTSAAL

11:10 - 11:35Type 2 immunity controls resolution of helminth-induced lung infl ammation: David Voehringer (DE)

11:35 - 12:00The role of TH2 cytokines in cutaneous immune responses: Kenji Kabashima (JP)

12:00 - 12:25Pro-resolving and anti-infl ammatory effects of TH2 immune responses in arthritis: Aline Bozec (DE)

12:25 - 12:35O001 - Essential role of C-REL in IL-33-mediated activation of group 2 innate lymphoid cells: B. C. Mindt (CA)* - C. U. Duerr - M. Mancini - S. M. Vidal - P. Gros - D. Langlais - J. H. Fritz

12:35 - 12:45O002 - Effective treatment of experimental asthma by lung-restricted inhibition of janus kinase 1:N. Ghilardi (US)*

10:40 - 11:10COFFEE BREAK & VISIT THE EXHIBITION

EXHIBIT AREA

15

13:15 - 13:25O005 - Interleukin-11 drives autoimmune pathologies through the induction of a unique CD4+ TH17 population: T. Putoczki (AU)* - K. Y. Fung - C. Louis - R. Metcalfe - I. Wicks - M. Griffi n

13:25 - 13:35O006 - Understanding the molecular signature and function of IL-22BP producing T cells: M. Sabihi (DE)* - P. Pelczar - S. Huber on behalf of AG Huber

13:35 - 13:45O007 - IL-38 ameliorates skin infl ammation and limits IL-17 production from GD T cells: A. Huard (DE)* - Y. Han - J. F. Mora - P. da Silva - S. Wiechmann - C. Schuster - P. Billuart - C. Sala - H. Burkhardt - M. J. Parnham - A. Ernst - B. Brüne - A. Weigert

13:45 - 13:55O008 - Suppression of STAT1 signaling shapes the functional identity of CD4+ T cells in infl ammatory arthritis: A. C. Figueras (UK)* - J. Twohig - R. Andrews - F. Wiede - B. Cossins - A. Derrac Soria - M. Lewis - M. Townsend - D. Millrine - J. Li - D. Hill - X. Liu - B. Szomolay - C. Pepper - P. Taylor - C. Pitzalis - T. Tiganis - N. Williams - G. Jones - S. Jones

13:55 - 14:05O009 - Increased T cell polyreactivity with marked accumulation of TNF-A DP (CD4+CD8+) in the synovial tissue of pre-RA, arthralgia subjects:A. Floudas (IE)* - D. J. Veale - U. Fearon

14:05 - 14:15Sidney & Joan Pestka Post-Graduate Award Winner: O010 - TBET provides survival advantage to Tregs during systemic interferon gamma driven immune responses: B. Akkaya (US)* - M. Akkaya - J. Al Souz - M. Pena - A. H. Holstein - M. Maz - J. Kabat - O. Kamenyeva - E. M. Shevach

Presentations with lunchSarah Gaffen (US) & Burkhard Becher (CH)

13:15 - 14:15ORAL ABSTRACT SESSION 1: WITH A FOCUS ON T CELLS

FESTSAAL

13:25 - 13:35O012 - TRAF7 Negatively regulates the type I IFNantiviral response: R. Lin (CA)* - Y. Liu - Z. Liu - L. Yang - M.-L. Goulet

13:35 - 13:45O013 - Viral complementation of immunodefi ciency confers protection against enteric pathogens via interferon lambda: H. Ingle (US)* - S. Lee - T. Ai - A. Overdahl - R. Rodgers - G. Zhao - M. Sullender - S. Peterson - M. Locke - T.-C. Liu - C. Yokoyama - B. Sharp - S. Schultz-Cherry - J. Miner - M. Baldridge

13:45 - 13:55O014 - Non-canonical CGAS signaling limits viral replication through CXCL1 expression and neutrophilia: F. Humphries (US)* - L. Shmuel-Galia - V. Kasparcova - S. Pesiridis - K. A. Fitzgerald

13:55 - 14:05O015 - Deciphering the mode of action of theRIG-I like receptor LGP2 in the interferon response triggered by viral infections: N. Gillich (DE)* - P. Scaturro - A. Pichlmair - M. Binder - R. Bartenschlager

14:05 - 14:15O016 - Type I and Type III interferons are natural adjuvants inducing distinct patterns of adaptive antiviral immunity: L. Ye (DE)* - D. Schnepf - J. Becker - K. Ebert - Y. Tanriver - V. Bernasconi - H. H. Gad - R. Hartmann - N. Lycke - P. Staeheli

Presentations with lunchFrancesca Barone (UK) & Stefan Rose-John (DE)

13:15 - 14:15ORAL ABSTRACT SESSION 2: WITH A FOCUS ON CYTOKINE SIGNALING

ZEREMONIENSAAL


14:15 - 15:50POSTER SESSION 1

POSTER AREA

12:45 - 14:15BREAK

16


16:00 - 16:25The impact of the IL-23/Th17 axis on the B cell response: Gerhard Krönke (DE)

16:25 - 16:50GM-CSF: T cell-phagocyte communication conduit:Burkhard Becher (CH)

16:50 - 17:15Neuronal-immune cell network regulates tissue response during infl ammation: Francesca Barone (UK)

17:15 - 17:25O017 - NK cell-derived GM-CSF potentiates autoantibody-induced infl ammatory arthritis and is negatively regulated by CIS: C. Louis (AU)* - F. S.-F. Guimaraes - N. Huntington - I. Wicks on behalf of the Walter and Eliza Hall Institute of Medical Research

17:25 - 17:35O018 - Multiomics: Low but differential expression of IFNγ has distinctive mechanistic features linking chronic infl ammation to autoimmunity: H. Young (US)* - R. Bae - D. Hodge - J. Fenimore - V. Thovarai - A. Dzutsev - G. Trinchieri - M. E. Gershwin

Sponsored by JanssenTracy McGaha (CA) & Yoshiya Tanala (JP)

16:00 - 17:35PARALLEL SESSION 4: REGULATION OF AUTOIMMUNITY AND AUTOIMMUNE DISEASE BY CYTOKINES

FESTSAAL

16:00 - 16:25Role of innate like T cells in combined gut and joint infl ammation: Dirk Elewaut (BE)

16:25 - 16:50Environmental infl uences on intestinal stem cell physiology: Brigitta Stockinger (UK)

16:50 - 17:15Innate immune cells drive intestinal tissue repair:Tom Cupedo (NL)

17:15 - 17:25O019 - The key role of cytokines in regulation of intestinal microbial homeostasis, infl ammation and atherosclerosis: E. Koltsova (US)* - A. Fatkhullina - I. Peshkova - T. Aghayev - A. Dzutsev - G. Trinchieri

17:25 - 17:35O020 - Role of IL-33-dependent innate immune responses in colitis-associated cancer: C. De Salvo (US)* - L. Lopetuso - K.-A. Buela - W. Goodman - L. Di Martino - T. Pizarro on behalf of Loris Lopetuso

Sponsored by Pfi zerCristina Bergamaschi (IT) & David Voehringer (DE)

16:00 - 17:35PARALLEL SESSION 5: CYTOKINE BIOLOGY MEETS THE GUT: INTESTINAL INFLAMMATION

ZEREMONIENSAAL

17

09:00 - 09:25TBA: Lucie Heinzerling (DE)

09:25 - 09:50Regulation of autoimmunity by PD-1 and LAG-3: Taku Okazaki (JP)

09:50 - 10:15Adverse events in pituitary and thyroid glands induced by immune checkpoint inhibitors: Shintaro Iwama (JP)

10:15 - 10:25O021 - Immune checkpoint receptor LILRB4: A new player in regulating viral infection: D. Verthelyi (US)* - H. Lee - M. Manangeeswaran - D. Ireland - A. Lewkozicz - I. McWilliams - K. Engel - M. Chowdhury

10:25 - 10:35O022 - Interleukin-6 is associated with resistance to anti-PDL1 tumor immunotherapy and promotes therapeutic resistance by inhibiting CD8+ T cells: N. West (US)* - K. Yuen - M. Huseni - J. Klementowicz - L. Wang - C. Orr - J. Peng - Y. Senbabaoglu - M. Merchant - L. Molinero - S. Mariathasan

Sponsored by the Japanese Society of Interferon & Cytokine ResearchGeorg Schett (DE) & Brigitta Stockinger (UK)

09:00 - 10:35PLENARY SESSION 2: CYTOKINE-RELATED DISEASES AFTER CHECKPOINT INHIBITION

FESTSAAL

Scientifi c Program - Tuesday 22 October

11:05 - 11:30Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-infl ammatory polarization: Atushi Kumanogo (JP)

11:30 - 11:55Bioenergetic strategies of pro-infl ammatory T cells:Cornelia Weyand (US)

11:55 - 12:20Systemic immunometabolism in viral infection:Andreas Bergthaler (AT)

12:20 - 12:30O023B - 2-Hydroxyglutarate is a critical regulator of macrophage function: N. Williams (IE)* - D. Ryan - A. Costa - L. O’Neill

12:30 - 12:40O024 - AMP-activated protein kinase supports increased mitochondrial oxidation necessary for type I interferon production by plasmacytoid dendritic cells: H. J. Hurley (US)* - Z. Rothkopf - H. Dewald - P. Deb - P. Fitzgerald-Bocarsly

Supported in part by an unrestricted educational grant from Cytokine JournalDhan Kalvakolanu (US) & Gerhard Krönke (DE)

11:05 - 12:40PARALLEL SESSION 7: IMMUNE METABOLISM REGULATING CYTOKINE PRODUCTION AND IMMUNE CELL POLARIZATION

FESTSAAL

11:05 - 11:30Blocking only the bad side of Interleukin-6 in infl ammation and cancer: Stefan Rose-John (DE)

11:30 - 11:55The ADAM17 protease triggers deregulated cytokine signaling and is a therapeutic target in lung diseases: Brendan Jenkins (AU)

11:55 - 12:20Therapeutic targeting of the cytokine signaling pathways: Peter Taylor (UK)

12:20 - 12:30O025 - The molecular basis of JAK/STAT inhibition by SOCS1: N. J. Kershaw (AU)* - N. P. Liau - N. A. Nicola - J. J. Babon

12:30 - 12:40O026 - Investigation of T cell protein tyrosine phosphatase in regulating cytokine and TCR signaling for infl ammatory skin disease therapy: W-J. Kim (KR)* - J.-H. Koo - J. H. Kim - M. S. Oh - E.-C. Shin - M. H. Sohn - J.-M. Choi

Sponsored by Eli Lilly and CompanyCem Gabay (CH) & Yoshiya Tanaka (JP)

11:05 - 12:40PARALLEL SESSION 8: THERAPEUTIC TARGETING OF THE CYTOKINE SIGNALING PATHWAYS

ZEREMONIENSAAL

10:35 - 11:05COFFEE BREAK & VISIT OF THE EXHIBITION

EXHIBIT AREA

18

13:10 - 13:20O033 - The structure of the interleukin 11 signaling complex guides therapeutic design: M. D. W. Griffi n (AU)* - R. D. Metcalfe - K. Aizel - C. O. Zlatic - P. M. Nguyen - P. R. Gooley - T. L. Putoczki

13:20 - 13:30O034 - NF-KB and NFAT pathways shape mesenchymal stem cell response to PAMPS: F. Tidu (CZ)* - M. De Zuani - K. Benidckova - S. S. Jose - J. Fric

13:30 - 13:40O035 - DAPK family members are negative regulators of RIG-I signaling: V. Goncalves Magalhaes (DE)* - J. Wolanski - J. Willemsen - M. Binder

13:40 - 13:50O036 - STAT1 displays functionally distinct phosphorylation upon LPS stimulation: H. Metwally (JP)* - T. Kishimoto

13:50 - 14:00O037 - STAT1 in myeloid cells promotes extramedullary haematopoiesis during MCMV infection and sterile infl ammation: T. Bulat (AT)* - R. Gawish - M. Biaggio - C. Lassnig - S. Macho-Maschler - A. Poelzl - N. Simonovic - H. Keresztes - M. Prchal-Murphy - V. Sexl - A. Krmpotic - S. Jonjic - M. Müller - B. Strobl

14:00 - 14:10O038 - Interleukin 6 trans-signaling controls liver regeneration after partial hepatectomy: J. Scheller (DE)* - N. Fazel Modares - R. Polz

Presentations with lunchBrendan Jenkins (AU) & Bryan Williams (AU)

13:10 - 14:10ORAL ABSTRACT SESSION 4: WITH A FOCUS ON TUMOR RESPONSES

ZEREMONIENSAAL

14:10 - 15:40POSTER SESSION 2

POSTER AREA


13:10 - 13:20O027 - Novel molecular inducers of CGAS-STING signaling exhibit diverse therapeutic and mechanistic impact: V. Defi lippis (US)*

13:20 - 13:30O028 - Regulation of the interferon-mediated antiviralresponse by novel oxidative post-translationalmodifi cation of STING: N. Grandvaux (CA)* - N. Zamorano - A. Fortin - E. Caron - S. Chartier

13:30 - 13:40O029 - Aberrant STING signaling in COPA syndrome: A. Steiner (AU)* - S. Davidson - S. L. Masters

13:40 - 13:50O030 - The intrinsic regulation of the STING-dependent type I interferon induction by the hepatic transmembrane serine protease, hepsin: H. M. Liu (TW)* - F. Hsin

13:50 - 14:00O031 - TNF-A signaling employs CGAS-STING totrigger interferon and interferon-stimulated geneinduction: J. Willemsen (CH)* - C. Tessier - D. Guerini - J. Zhang - M. Hasan - R. Siegel - J. Rush

14:00 - 14:10O032 - Molecular and cellular dissection of STING-associated vasculopathy with onset in infancy-(SAVI) mediated intestinal infl ammation:L. Shmuel-Galia (US)* - F. Humphries - K. A. Fitzgerald

Presentations with lunchRaphaela Goldbach-Mansky (US) & TBC

13:10 - 14:10ORAL ABSTRACT SESSION 3: WITH A FOCUS ON VIRAL RESPONSES

FESTSAAL

12:40 - 14:10BREAK

19


15:50 - 16:15Transcriptional control of myeloid cells: Irina Udalova (UK)

16:15 - 16:40Fuelling neutrophilic infl ammation:Sarah Walmsley (UK)

16:40 - 17:05Microbiota-neutrophil cross-talk in cancer therapy:Romina Goldszmid (US)

17:05 - 17:15O039 - Myeloid PTEN promotes obesity-induced insulin resistance: A. Vogel (AT)* - J. S. Brunner - A. Lercher - A. Korosec - O. Sharif - G. Schabbauer

17:15 - 17:25O040 - Identifi cation of distinct neutrophil populations in the peripheral blood of G-CSF treated donors:K. R. Martin (AU)* - D. Zalcenstein - P. Hickey - T. Baldwin - N. Wilson - I. Wicks

Scott Durum (US) & Georg Schett (DE)

15:50 - 17:25PARALLEL SESSION 9: TARGETING NEUTROPHILS AND MACROPHAGES IN IMMUNE-MEDIATED DISEASE

FESTSAAL

15:50 - 16:15Modes and outcome of IL-6 signaling into T cells:Thomas Korn (DE)

16:15 - 16:40The role of IL-6/gp130 dependent neuroimmune interactions and involvement of microRNAs in neuropathic pain disorders: Michaela Kress (AT)

16:40 - 17:05How does IL-6 determine infl ammatory outcome:Simon Jones (UK)

17:05 - 17:15O041 - Serine 727 phosphorylation of STAT1 modulates an IFN-A and IL-6 mediated neuroinfl ammatory disease: P. Songkhunawej (AU)*- M. J. Hofer

17:15 - 17:25O042 - IL-6 and IL-8 as systemic infl ammatory response in patients with septic arthritis: A. G. Rosas Taraco (MX)* - J. A. Gonzalez Chapa - V. M. Peña Martinez - G. M. Gonzalez Gonzalez - J. F. Vilchez Cavazos - R. D. J. Treviño Rangel - M. C. Salinas Carmona

Stephan Rose-John (DE) & Yuko Kaneko (JP)

15:50 - 17:25PARALLEL SESSION 10: ORCHESTRATION OF INFLAMMATORY RESPONSES BY IL-6

ZEREMONIENSAAL

17:25- 18:10ICIS MEMBERS MEETING AND DISTRIBUTION OF TRAVEL AWARDS

FESTSAAL

19:15 - 23:00NETWORKING DINNER - Additional registration required

VIENNA TOWN HALL

Rathaus

Hofburg Conference Center

20

Scientifi c Program - Wednesday 23 October

09:00 - 09:25The epithelial IFN: IFN-kappa and its role in health and disease: Johann Gudjonsson (US)

09:25 - 09:50Type I interferons in an expanding spectrum of autoinfl ammatory diseases: Raphaela Goldbach Mansky (US)

09:50 - 10:15Cytokine interference in infection: Anne O’Garra (UK)

10:15 - 10:25Milstein Young Investigator Award Winner Presentation: O043 - Phosphorylation of STAT2 on T404 is critical for interferon-mediated signaling and antiviral defense: Y. Wang (US)* - X. Wang - C. Zhao - B. Willard - J. Yang - G. Stark

10:25 - 10:35The Christina Fleischmann Award to Young Women Investigators Award Winner Presentation: O044 - The ETS transcription factor ELF1 triggers a critical wave of gene expression in the antiviral response to Type I interferon: M. Dittmann (US)* - C. Si - L. L. Seifert - D. Saha - M. de Vries - G. Wang - M. Sadic - A. Briley - U. Schaefer - A. M. Valero-Jimenez - A. García-Sastre - S. Tripathi - B. R. Rosenberg

10:35 - 10:45Milstein Young Investigator Award Winner Presentation: O044B - Model for studying interferon-mediated control of inter- and intra-species virus transmission and evolution: R. A. Langlois (US)* - E. Fay - K. Balla - S. Kotenko - D. Masopust - N. Elde

Sponsored by Bristol-Myers SquibbAnne O’Garra (UK) & Thomas Decker (AT)

09:00 - 10:45PARALLEL SESSION 11: TYPE I INTERFERONS: BIOLOGY AND THEIR ROLE IN DISEASE

FESTSAAL

09:05 - 09:25An update on the pathogenic role of IL-6 in rheumatic diseases: Yuko Kaneko (JP)

09:25 - 09:45IL-6 as a key mediator linking infl ammation and structural bone changes in arthritis: Georg Schett (DE)

09:45 - 10:05Cumulative and updated evidence of IL-6 signaling inhibition in RA: Tsutomu Takeuchi (JP)

10:05 - 10:25Systemic effect of IL-6 blockade beyond the joints:Cem Gabay (CH)

Sponsored by Chugai Pharmaceutical Co., LtdGeorg Schett (DE) & Yoshiya Tanaka (JP)

09:05 - 10:25PARALLEL SESSION 12: NOVEL ASPECTS OF IL-6 INHIBITION IN DISEASE

ZEREMONIENSAAL

10:45 - 11:05COFFEE BREAK & VISIT THE EXHIBITION

EXHIBIT AREA

21

11:05 - 11:30PU.1 – Core regulator of fi broblast polarization and tissue fi brosis: Andreas Ramming (DE)

11:30 - 11:55Distinct fi broblast subsets mediate infl ammation or tissue damage in arthritis: Chris Buckley (UK)

11:55 - 12:20Innate immune signaling in infl ammatory skin/joint disease and lung fi brosis: Erwin Wagner (ES)

12:20 - 12:30O045 - Interferon-induced transmembrane protein 3 (IFITM3) prevents cardiac fi brosis and electrical dysfunction during infl uenza virus infection:J. Yount (US)* - A. Kenney - M. Rajaram

12:30 - 12:40O046 - Role of suppressor of cytokine signaling 1 (SOCS1) in regulating the fi brogenic response of hepatic stellate cells: R. Kandhi (CA)* - A. Menendez - S. Ramanathan - S. Ilangumaran

12:40 - 12:50Milstein Young Investigator Award Winner Presentation: O046B - Interleukin-18 alters cellular organization in choroidal neovascular lesions:S. Doyle (IE)* - E. Ozaki - K. Brennan - E. Connolly - M. Campbell

Sponsored by NovartisDavid Millrine (UK) & Tsutomu Takeuchi (JP)

11:05 - 12:50PARALLEL SESSION 13: CYTOKINE-MEDIATED RESIDENT TISSUE DESTRUCTION AND FIBROTIC RESPONSES

FESTSAAL

11:05 - 11:30Interleukin-1: A key player in cerebrovascular disease: Stuart Allan (UK)

11:30 - 11:55Escalating infl ammation: Stressed monocytes switch from vesicular to gasdermin D-mediated IL-1B secretion: Anna Rubartelli (IT)

11:55 - 12:20The role of IL-1 family cytokines in vaccine adjuvanticity: Ed Lavelle (IE)

12:20 - 12:30O047 - Interleukin-33 promotes central nervous system synapse remodeling: I. D. Vainchtein (US)* - H. Nakao-Inoue - G. Chin - A. V. Molofsky

12:30 - 12:40O048 - SARM regulates IL-1 production yet contributes to pyroptosis following AIM2 infl ammasome activation: M. Carty (IE)* - J. Kearney - R. Sugisawa - K. A. Shanahan - A. G. Bowie

12:40 - 12:50The Sidney & Joan Pestka Graduate Award Winner Presentation: O048B - A multi-component bacterial toxin incites host infl ammation via the NLRP3 infl ammasome: A. Mathur (AU)* - S. Feng - J. A. Hayward - C. Ngo - D. Fox - S. M. Man

Leo Joosten (NL) & Cem Gabay (CH)

11:05 - 12:50PARALLEL SESSION 14: LOCAL AND SYSTEMIC EFFECTS OF IL-1 FAMILY CYTOKINES IN DISEASE

ZEREMONIENSAAL


12:50 - 14:00BREAK

22

Presentations with lunchKate Fitzgerald (US) & Howard Young (US)

13:00 - 14:00ORAL ABSTRACT SESSION 5: WITH A FOCUS ON INFECTION BIOLOGY

FESTSAAL

13:00 - 13:10O055 - Human nasal commensal staphylococcus epidermidis enhances IFN-α-dependent immunity against infl uenza virus: H. J. Kim (KR)* - A. Jo - J. Won - C. H. Gil - C.-S. Rhee

13:10 - 13:20O056 - Type I interferon-driven pathogenic angiogenesis initiated by antimicrobial killing of B.Oleronius during fl are UPS of rosacea:A. Mylonas (CH)* - H. Hawerkamp - Y. Wang - S. Meller - B. Homey - J. Di Domizio - L. Mazzolai - M. Gilliet - A. Hovnanian - C. Conrad

13:20 - 13:30O057 - Inhibition of interferon signaling by shigella effectors: C. Odendall (UK)* - A. Voak

13:30 - 13:40O058 - Different responsiveness to GM-CSF of bone marrow cells determines susceptibility against mycobacterium tuberculosis infection by regulating neutrophilic infl ammation: E. Choi (KR)* - S. M. Kang - S. J. Shin - K. W. Kwon

Presentations with lunchMariana Kaplan (US) & Nancy Reich (US)

13:00 - 13:50ORAL ABSTRACT SESSION 6: WITH A FOCUS ON STING PATHWAY

ZEREMONIENSAAL

13:00 - 13:10O049 - Pivotal roles of the CX3CL1-CX3CR1 axis in skin carcinogenesis: Y. Ishida (JP)* - Y. Kuninaka - Y. Yamamoto - M. Nosaka - F. Furukawa - N. Mukaida - T. Kondo

13:10 - 13:20O050 - Immunosuppression by CX3CR1- dependent monocytes in cancers: A real-time intravital characterization: K. Jung (KR)* on behalf of Lab of Cancer Immunology and In Vivo Imaging

13:20 - 13:30O051 - STAT3 deletion enhances small cell lung cancer metastasis: D. Gough (AU)* - A. Guanizo - J. Chen - W. S. Jayasekara - S. Gordon - D. N. Watkins

13:30 - 13:40O052 - Specifi c targeting of Type I interferon to the tumor microenvironment or to dendritic cells as a novel, generic and safe cancer immunotherapy:A. Cauwels (BE)* - S. Van Lint - A. Van Parys - F. Paul - G. Garcin - B. Vandekerckhove - N. Kley - G. Uze - J. Tavernier

13:40 - 13:50O053 - The gain-of-function STAT5B N642H mutation as a driver of mature T cell leukemia/lymphoma:H. Neubauer (AT)* - T. Suske - H. Pham - S. Zahma - S. Tangermann - M. Prchal-Murphy - B. Maurer - V. Sexl - P. Valent - A. Boersma - T. Rülicke - V. Bekiaris - L. Kenner - R. Moriggl

13:50 - 14:00O054 - Il-15 defi cient colon carcinomas have decreased cytolytic lymphocytes and skewed myeloid cell populations: K. S. Schluns (US)* - C.-C. Chou - R. M. Santana Carrero - S. M. Hegde


23


14:00 - 14:40Keynote Lecture 2: A new look at interferon signaling: Thomas Decker (AT)

14:40 - 15:05C-type lectins: Unrecognised master regulators of immunity: Gordon Brown (UK)

15:05 - 15:30Context dependent action of STAT3 in KRAS oncogenesis: Nancy Reich (US)

15:30 - 15:35Invitation to Cytokines 2020 in Seattle

14:00 - 15:35PLENARY SESSION 3: PATTERN RECOGNITION RECEPTORS IN IMMUNITY AND DISEASE

FESTSAAL

8th Annual Meeting of the International Cytokine &

Interferon Society

Hyatt Regency Seattle, USA

1 - 4 November

Structure-Function & Systems Biology of Cytokines

www.seattle.cytokinesociety.org

Michael J. Gale, ChairUniversity of Washington

Ram Savan, Co-ChairUniversity of Washington

Steve ZieglerBenaroya Research Institute

Yueh-Ming LooAstraZeneca

Sarah Gaffen University of Pittsburgh

Reneé C. IretonUniversity of Washington

Naeha SubramanianInstitute for Systems Biology

The Mary Ann Liebert, Inc./Journal of Interferon and Cytokine Research Symposium in Honor of Philip I. MarcusMichael Gale (US)

Antibodies Recognize Antigens...

How will you get recognized for your immunology research?

Science Immunology publishes original, peer-reviewed, science-based research articles that report critical advances in all areas of immunological research, including important new tools and techniques.

Submit your research today. Learn more at: ScienceImmunology.org

@SciImmunology@ScienceImmunology

26

Poster Session 1 - Monday 21 October

ANTI-CYTOKINE THERAPYHighlighted posters will part of a poster tour

chaired by Stefan Rose-John (DE)

P001 - MONOBODY APPROACH TO TARGET THE DARK SIDE OF INTERLEUKIN-22 SIGNALING / C. Michiels* - G. La Sala - O. Hantschel - L. Dumoutier

P002 - NEUTROPHILS BUT NOT EPITHELIAL CELLS REQUIRE TYROSINE KINASE 2 FOR INTERFERON-LAMBDA-MEDIATED GENE EXPRESSION / D. Schnepf* - M. Stanifer - L. Polcik - A. Ohnemus - J. Vier - T. Thamamongood - H. H. Gad - R. Hartmann - G. Häcker - M. Schwemmle - B. Strobl - S. Kirschnek - S. Boulant - P. Staeheli

P003 - MODULATION OF THE IL-6 SIGNALING PATHWAY IN LIVER CELLS BY MIRNAS TARGETING GP130, JAK1 AND/OR STAT3 / I. Behrmann* - F. A. Servais - M. Kirchmeyer - M. Hamdorf - N. W. Minoungou - S. Rose-John - S. Kreis - C. Haan

P005 - FUSION PROTEINS OF IL-2/IL-15RBETA AND COMMON GAMMA CHAIN FOR DETECTION AND INHIBITION OF IL-15/IL-15RALPHA COMPLEXES / K. Gerardo Chouman* - A. Küster - H. Schmitz-Van de Leur - S. Ernst - G. Müller-Newen

P006 - USING PARTIAL LEAST SQUARES REGRESSION 2 ANALYSIS OF SERUM CYTOKINE AND CHEMOKINE PATTERNS TO CLASSIFY CASTLEMAN’S DISEASE AND RHEUMATOID ARTHRITIS / K. Uno* - K. Yoshizaki - M. Tanigawa - H. Fujimiya

P007 - CYCLO (VAL-PRO) ATTENUATES RENAL INJURY BY INHIBITING PRO-INFLAMMATORY CYTOKINES IN MICE RENAL ISCHEMIC MODEL / K. Hira* on behalf of A. Sajeli Begum

P008 - DISSECTING THE CYTOKINE HIERARCHY DRIVING DISEASE IN A MOUSE MODEL OF THE CYTOKINE RELEASE SYNDROME / L. Nouveau* - L. Cons - L. Chatel - W. Ferlin

P009 - INTERLEUKIN-2 TREATMENT INHIBITS FOLLICULAR CYTOTOXIC CD8 T CELLS AND DETERIORATES CD8 T CELL-MEDIATED IMMUNOPATHOLOGY DURING VIRAL INFECTION / P. Zhou* - D. Yu

P010 - CYTOKINES INHIBITION EFFECT OF STANDARDIZED EXTRACT OF AN ENDOPHYTIC FUNGI FROM PIPER NIGRUM L / P. P. Pal* - A. S. Begum

P011 - TARGETING IL-1B PATHWAY FOR CANCER IMMUNOTHERAPY / P. Jayaraman* - C. Wong - N. O’Brien - R. Diwanji - R. Linnartz - K. Rose - V. Rodrik-Outmezguine - M. Pelletier - A. Savchenko - T. Luo - V. Rezek - S. Kitchen - D. Slamon - J. Baum - C. Sabatos-Peyton - G. Dranoff

P012 - THE STRUCTURE OF IL-11 MUTEIN SUGGESTS A SURPRISING MECHANISM OF INHIBITION / R. D. Metcalfe* - K. Aizel - P. M. Nguyen - C. O. Zlatic - P. R. Gooley - T. L. Putoczki - M. D. W. Griffin

P013 - ATTENUATION OF IL-18 LEVELS AND ACTIVITY BY RUXOLITINIB IN A MURINE MODEL OF HYPERINFLAMMATION / S. Albeituni* - K. C. Verbist - R. Das - R. Bassett - K. E. Nichols

P014 - SMALL-MOLECULE INHIBITORS OF PRO-INFLAMMATORY CYTOKINES (TNF-A, IL-6 AND IL-1B) EFFECTIVE UNDER LPS-INDUCED MOUSE ENDOTOXEMIA MODEL / S. B. Ahil* - S. K. S - K. Hira

P015 - TARGETING PROLONGED STAT3 ACTIVATION IN GBM CANCER STEM CELLS / S. Wightman* - Y. Wang - T. Alban - J. Lathia - G. Stark

P016 - TARGETING NLRP3 FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES / S. E. Corcoran* - L. O’Neill

P018 - MODULATION OF CYTOKINE ACTIVITY BY TETRACYCLINE AND DOXYCYCLINE ALTERS DISEASE COURSE IN EXPERIMENTAL EBOLA, MARBURG AND LASSA VIRUS INFECTIONS / T. M. Fredeking* - G. Ignatyev - A. Atrasheuskaya

P019B - MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATING PEPTIDE, AES-16-2M PROMOTES ITGB1 THROUGH WOUND HEALING IN HUMAN DERMAL FIBROBLASTS / H. Kim*

P019C - MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATING PEPTIDE, AES-16-2M PROMOTES ITGB1 THROUGH WOUND HEALING IN HUMAN DERMAL FIBROBLASTS / H. Kim* - Y. Yang - S-I. Bang

P019D - MICROWAVE PLASMA ENHANCES WOUND HEALING EFFECTS BY THE RELEASE OF NITRIC OXIDE AND INDUCTION OF ERK PATHWAY / M. Jeon* - Y. Yang - S.-I. Bang

P019E - EVALUATION OF THE ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY OF ANCHOMANES DIFFORMIS IN A DIABETIC ANIMAL MODEL / O. Oguntibeju*

AUTOINFLAMMATION AND AUTOIMMUNITY Highlighted posters will part of a poster tour

chaired by Tracy L. McGaha (CA)

P020 - B AND T CELL PHENOTYPE AND FUNCTION IN THE SYNOVIAL TISSUE OF ACPA+ AND ACPA- RHEUMATOID ARTHRITIS PATIENTS / A. Floudas* - C. Low - M. Biniecka - D. J. Veale - U. Fearon

P021 - INCREASED T CELL PLASTICITY WITH DYSREGULATION OF TFH, TPH AND TREG CELL RESPONSES IN CHILDREN WITH JIA AND DOWN SYNDROME-ASSOCIATED ARTHRITIS / A. Floudas* - C. Foley - M. Canavan - M. Biniecka - E. J. MacDermott - D. J. Veale - R. H. Mullan - O. G. Killeen - U. Fearon

P022 - MACROPHAGE-DERIVED HIV-1 CARRIES BIOACTIVE TGF-BETA / A. Arakelyan* - J. Petersen - L. Margolis

P023 - A CRITICAL ROLE FOR CEREBRAL ENDOTHELIAL CELLS IN THE MEDIATION OF INTERFERONOPATHIC BRAIN DISEASE / B. Viengkhou* - S. McGlasson - I. L. Campbell - D. Hunt - M. J. Hofer

P024 - INHIBITION OF IRF5 HYPER-ACTIVATION PROTECTS FROM LUPUS ONSET AND SEVERITY / S. Song - S. De - S. Sun - M. He - Y. Al-Abed - C. Aranow - M. Mackay - W. Clapp - B. Barnes*

27


P025 - EX-VIVO BENEFICIAL EFFECT OF INTERFERON-B TREATMENT ON INFLAMMATORY MEDIATORS PROFILE VIA SUPPRESSION OF INOS SIGNALING PATHWAY IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME / S. Benchabane - M. Belkhelfa - H. Belguendouz - S. Zidi - A. H. Boudjelida - C. Touil-Boukoffa*

P026 - CONTROL OF THE TH17/IL-17 AXIS BY GP130-SIGNALING CYTOKINES REGULATES THE DEVELOPMENT AND FUNCTION OF ECTOPIC LYMPHOID STRUCTURES IN AUTOIMMUNITY AND CANCER / D. Hill* - D. Lucchesi - L. Yu - A. Cardus - B. Cossins - R. Coleby - E. Pontarini - R. Andrews - B. Szomolay - N. Williams - C. Pitzalis - M. Bombardieri - B. Jenkins - S. Jones - G. Jones

P027 - WHOLE BLOOD RETROELEMENT ACTIVITY IN EARLY RA IS INCREASED IN B CELLS AND POSITIVELY ASSOCIATES WITH ACPA BUT IS INDEPENDENT OF THE INTERFERON GENE SIGNATURE / F. A. Cooles* - G. Vidal-Pedrola - B. Millar - N. Naamane - A. G. Pratt - C. M. Hilkens - A. E. Anderson - R. Shukla - J. D. Isaacs

P028 - INTERLEUKIN-1 AND IL-23 INDUCE PATHOGENIC FUNCTION OF MEMORY-LIKE TH17 CELLS IN AUTOIMMUNE ENCEPHALOMYELITIS / H.-G. Lee* - J.-U. Lee - D.-H. Kim - S. Lim - I. Kang - J.-M. Choi

P031 - SATB1 CONTROLS GM-CSF AND PD-1 EXPRESSION BY PATHOGENIC TH17 CELLS / K. Hirota* - K. Yasuda - Y. kitagawa - R. Kawakami - H. Watanabe - G. Kondoh - S. Sakaguchi

P034 - CTLA-4 FUSION PROTEIN SUPPRESSES SAC-INDUCED TNF-ALPHA AND IL-6 PRODUCTION IN B CELLS / M.-H. Chen*

P035 - THE IL-17 CYTOKINES AND RECEPTORS FAMILY DURING CHRONIC RESPIRATORY INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA: THE RELEVANCE IN HOST DEFENSE AND IMMUNOPATHOLOGY / G. Rizzo - A. Migliara - F. Saliu - B. Sipione - A. Bragonzi - C. Cristina - A. Lombardo - N. I. Lore’*

P036 - THE ROLE OF MICRORNAS AS DETERMINANTS OF DISEASE HETEROGENEITY IN INFLAMMATORY ARTHRITIS / R. H. Jenkins* - D. G. Hill - A. Cardus Figueras - B. Cossins - R. Andrews - G. W. Jones - S. A. Jones

P038 - INHIBITORY ROLE OF FC GAMMA RIIB IN THE PATHOGENESIS OF IGA NEPHROPATHY / S.-M. Ka* - T.-J. Lin - C.-H. Chen - C.-C. Wu - Y.-J. Hsu - J.-F. Chang - F.-C. Liu - A. Chen

P040 - ESSENTIAL ROLE OF IL-17A IN TREGS INDUCTION IN AUTOIMMUNE UVEITIS / W. P. Chong* - Y. Zhong - M. J. Mattapallil - J. Chen - R. R. Caspi

CYTOKINE REGULATIONHighlighted posters will part of a poster tour

chaired by Cem Gabay (CH)

P041 - ANTIINFLAMMATORY, ANTIFIBROTIC AND ANTIOXIDANT EFFECTS OF ALLIIN (S-ALLYL CYSTEINE SULFOXIDE) IN THE LIVER OF MICE WITH HIGH-FAT DIET INDUCED-OBESITY / A. S. M. Zepeda Morales - I. M. Borunda Calderón - M. D. L. Orozco Rangel - A. M. Sánchez Sánchez - E. M. Franco Torres - R. I. López Roa*

P042 - CYTOKINE-REGULATING ACTIVITY OF THE INTERFERON INDUCER / A. Narovlyansky* - A. Ivanova - V. Poloskov - M. Mezentseva - I. Suetina - L. Russu - A. Izmest’eva - E. Gerasimova - T. Ospelnikova - A. Sarymsakov - F. Ershov

P043 - EXPRESSION OF PROINFLAMMATORY CYTOKINES IS REGULATED BY C-ABL-PARP1-P65 (RELA) SIGNALING PATHWAY / A. A. Bohio* - R. Wang - R. K. Sah - Y. Ke - X. Ba

P044 - POST-TRANSLATIONAL REGULATION OF STAT1 TYR701 PHOSPHORYLATION: SUMOYLATION VS. ADP-RIBOSYLATION / A. Begitt* - S. C. Krause - M. Droescher - U. Vinkemeier

P045 - SERTOLI CELLS SUPRESS TNFA AND ENHANCE IL-10 PRODUCTION IN HEART AFTER MYOCARDIAL INFARCTION IN MICE / B. Porubská* - M. Hájková - M. Krulová

P047 - EARLY IFNB SECRETION DETERMINES VARIABLE DOWNSTREAM IL-12P70 RESPONSES IN HEALTH AND DISEASE / C. Posseme* - B. Charbit - A. Llibre - V. Bondet - V. Saint-Andre - A. Bisiaux - B. Piasecka - E. Nemes - T. Scriba - S. Pol - M. L. Albert - L. Quintana-Murci - D. Duffy - T. Milieu Interieur consortium

P048 - REGULATION OF K63 UBIQUITIN SIGNALING BY THE INNATE IMMUNE SENSOR LGP2 / C. M. Horvath*

P049 - LOSS OF HEPATIC MACROPHAGE RESERVOIR DUE TO DECREASED CSF1 PRODUCTION MIGHT BE RESPONSIBLE FOR COMPROMISED RESOLUTION OF DAMAGE AND INCREASED SCARRING IN CHRONIC LIVER INJURY / D. Kumar* - S. Subham - A. Kumar

P050 - DISCOVERY AND SCREENING OF PROTEIN BIOMARKERS WITH THE FIREPLEX® TECHNOLOGY PLATFORM / E. Atabakhsh* - A. Perea - R. Neuner - B. Heinrich - W. Austin - C. Rafferty - M. Camilleri - L. To - J. Murray - D. Pregibon

P051 - IL-36 CYTOKINES AS MEDIATORS OF VASCULAR FUNCTION / E. Fahey* - S. L. Doyle

P052 - BIOLOGY AND CHARACTERIZATION OF COVALENTLY LINKED INTERLEUKIN-10 / F. O. Minshawi* - W. Muller

P053 - AGE-RELATED CHANGES OF ADIPOCYTOKINES AND INTERLEUKINS IN HEALTHY INDIVIDUALS / I. Pantsulaia* - T. Atamashvili - M. Jgarkava - G. Devidze

P054 - DIFFERENTIAL IL-2RB ORGANIZATION IN MEMORY AND NAÏVE CD8+ T CELLS MODULATES IL-15 SENSITIVITY / I. Z. Fernandez* - D. Stitch - S. Thompson - J. Jacobelli - R. Kedl

P057 - ROLE OF THE SPINAL PURINERGIC EXPRESSION IN CFA INDUCED CHRONIC PAIN MODEL / L. Ducza* - A. Gajtko - R. Takacs - K. Holló

P058 - WIDESPREAD PROTEIN PHOSPHORYLATION AS A NOVEL MECHANISM FOR TYPE I INTERFERONS TO MEDIATE CELLULAR RESPONSES / B. Viengkhou - M. White - S. Cordwell - M. J. Hofer*

P059 - DEFINING AND ENGINEERING THE MOLECULAR BASIS OF INTERLEUKIN 12 FAMILY CYTOKINE BIOGENESIS / M. J. Feige*

28


P060 - ROLE OF INTRATHROMBOTIC CX3CR1-FRACTALKINE AXIS DURING RESOLUTION ON STASIS-INDUCED MURINE DEEP VEIN THROMBOSIS MODEL / M. Nosaka* - Y. Ishida - A. Kimura - Y. Kuninaka - T. Michiue - H. Yamamoto - N. Mukaida - T. Kondo

P062 - ALLIIN IMPROVES ENERGY BALANCE AND INSULIN RESISTANCE BY MODULATING THE SYNTHESIS AND EXPRESSION OF LEPTIN AND RESISTIN IN A DIO MICE MODEL / R. I. Lopez* - T. Garcia Iglesias - D. Ortuño Sahagún - L. Carrera Quintanar - A. S. Zepeda Morales - M. Alvarez Zavala - N. N. Franco Arroyo - A. M. Sanchez-Sanchez

P063 - ROLE OF CYTOKINES IN EXPERIMENTAL HEMORRHOIDS TREATED WITH BLUMEA LACERA (BURM.F.) DC. LEAVES (EBL) IN RATS / S. Hemalatha* - T. Dubey - K. Bhanukiran

P064 - CARDIOTROPHIN-LIKE CYTOKINE PROMOTES MYELOPOIESIS / S. Pasquin* - A. J. Tormo - J. Moreau - V. Laplante - M. Sharma - J.-F. Gauchat - M. Rafei

P065 - MODULATION OF LIVER FIBROGENESIS BY IL-37 / S. Mountford* - H. Noll-Puchta - A. Ringleb - L. Griessmair - G. Denk - F. Reiter - C. Dinarello - P. Bufler

P066 - CYTOKINE EXPRESSION IN THE TEAR FLUIDS OF DIABETIC PATIENTS IN THE PRESENCE AND ABSENCE OF DRY EYE DISEASE / S. Hagan* - A. S. Konstantinou - M. Byambajav

P067 - INDUCTION OF ONCOSTATIN M EXPRESSION BY ACUTE EXERCISE IN THE SKELETAL MUSCLES AND SERA OF MICE / T. Komori* - Y. Morikawa

P069 - THE INTERPLAY OF CYTOKINE RESPONSE AND CYTOMEGALOVIRUS DYNAMICS / U. Rand* - T. Kubsch - B. Kasmapour - L. Cicin-Sain

P070 - FUNCTIONAL ROLES OF ONCOSTATIN M IN THE PATHOGENESIS OF NONALCOHOLIC STEATOHEPATITIS IN MICE / Y. Morikawa* - T. Komori

P070A - DICER1 LEVELS OF EXPRESSION AS A THRESHOLD FOR REGULATION OF INFLAMMATION AND LIFE-SPAN THROUGH CANONICAL AND NON-CANONICAL FUNCTIONS / A. De Cauwer* - A. Mariotte - S. Bahram - P. Georgel

P070B - A SWITCH TO STAT5-REGULATED MYC EXPRESSION EXPLAINS THE DEVELOPMENT OF IFN IN MALIGNANT MELANOMA / I. Ghazawi - S. Cutle - M. Sajinovic - G. McArthur - S. John Ralph - A. Sleiman Mellick*

P070C - 3-D CHROMATIN INTERACTOME AND CYTOKINE-MEDIATED TRANSCRIPTIONAL REGULATION IN PRIMARY HUMAN T CELLS / P. Li* - W. J. Leonard

P070D - THE REGULATION OF IL-17 RECEPTOR SIGNALING BY KINASES TBK1 AND IKKE / D. Knizkova* - H. Draberova - S. Janusova - A. Drobek - O. Stepanek - P. Draber

P070E - CYTOKINE BLOOD PLASMA PROFILE OF PREMATURE NEWBORNS AFTER THERAPY WITH IFN ALPHA-2B AS A PART OF A COMBINED CONGENITAL PNEUMONIA THERAPY / A. Shuvalov*

INNATE IMMUNITY Highlighted posters will part of a poster tour

chaired by Nancy Reich (US)

P071 - JAPANESE ENCEPHALITIS VIRUS (JEV)-INDUCED MIR-301A SKEW MICROGLIAL PHENOTYPE TO M1 VIA SUPPRESSION OF NF-AB REPRESSION FACTOR / A. Basu*

P073 - GOLD NANOPARTICLES CAN MODULATE INNATE IMMUNE MEMORY IN HUMAN PRIMARY MONOCYTES AND MACROPHAGES / B. J. Swartzwelter* - D. Boraschi - P. Italiani

P074 - THE ROLE OF DEAD-BOX RNA HELICASE DDX42 IN REGULATING INTRACELLULAR INFECTIOUS BURSAL DISEASE VIRUS (IBDV) REPLICATION / C. Xu* - Y. Li - J. Lei - B. Hu

P075 - THE ROLE OF SARM IN TRANSCRIPTIONAL REGULATION OF IMMUNE GENES / C. G. Doran* - F. M. Roche - K. Hokamp - A. G. Bowie

P076 - POSITIVE REGULATORY ROLE OF THE E3 UBIQUITIN LIGASE TRIM65 DOWNSTREAM THE IFNB INDUCTION PATHWAY / D. N. Fonseca* - L. Miorin - G. Pisanelli - A. Garcia-Sastre

P077 - INTRACELLULAR LIPID DROPLET ACCUMULATION OCCURS EARLY FOLLOWING VIRAL INFECTION AND IS REQUIRED FOR AN EFFICIENT INTERFERON RESPONSE / E. Monson* - K. Crosse - M. Smith - E. Duan - W. Chen - K. Helbig

P078 - PROPOLIS DRIVES HUMAN MONOCYTES TO A PRO-INFLAMMATORY ACTION DURING THE TREATMENT WITH DOCETAXEL / E. O. Cardoso* - K. B. Santiago - F. L. Conte - J. C. Z. Rodrigues - K. I. Tasca - G. G. Romagnoli - J. K. Bastos - J. M. Sforcin

P079 - INNATE IMMUNE RESPONSE DRIVEN BY INCOMING INFLUENZA A VIRUS POLYMERASE / E. Fay* - S. Aron - M. Macchietto - S. Shen - R. Langlois

P080 - POTENTIAL ANTIVIRAL EFFECT OF TYPE III INTERFERONS ON DENGUE VIRUS REPLICATION IN MONOCYTES AND M1/M2 MACROPHAGES / E.-H. Hwang* - H. Oh - G. Kim - J.-H. Park - B.-S. Koo - F. Villinger - J. J. Hong

P081 - IMMUNE MODULATION AND CMV REACTIVATION IN SEPSIS-INDUCED IMMUNOSUPPRESSION / G. R. Lambe* - F. N. Kapadia

P083 - A GENOME-WIDE CRISPR SCREEN IDENTIFIES BRD9 AS A NEW DRUGGABLE COMPONENT OF THE HUMAN TYPE I INTERFERON SYSTEM / J. Börold* - D. Eletto - I. Busnadiego - B. Hale

P085 - MACROPHAGE METABOLIC REPROGRAMMING IN PRIMARY IMMUNODEFICIENCY SYNDROMES /K. McCann* - S. Holland

P086 - VIPERIN IS PRESENT IN THE DSDNA SIGNALOSOME AND FACILITATES EFFICIENT TBK1 UBIQUITINATION / K. Crosse* - E. Monson - M. Smith - K. Van der Hoek - N. Marsh - P. Revill - M. Beard - K. Helbig

P087 - GETTING TO KNOW YOUR IL-1 CYTOKINES - THE DISTINCT ROLES OF IL-1A AND IL-1B / K. Eislmayr* - A. Bestehorn - P. Kovarik

29


P089 - TRANSCRIPTIONAL REGULATION OF CYTOKINE INDUCTION BY PYHIN PROTEINS / M. Baran* - P. Slivka - J. L. Swantek - A. J. Slavin - A. G. Bowie

P091 - STAT3 COOPERATES WITH PHOSPHOLIPID SCRAMBLASE 2 TO SUPPRESS TYPE I INTERFERON-INDUCED ANTIVIRAL AND INFLAMMATORY RESPONSE / M.-H. Tsai* - C.-K. Lee

P092 - THE ROLE OF THE STAT1 C-TERMINAL TAD IN CHROMATIN REMODELLING IN PRIMARY MACROPHAGES / M. J. Ola* - K. Meissl - L. Amenitisch - A. Pölzl - M. Krunic - M. Farlik - N. Fortelny - M. Dolezal - F. Ruge - C. Bock - M. Müller - B. Strobl

P093 - 2-HYDROXYGLUTARATE IS A CRITICAL REGULATOR OF MACROPHAGE FUNCTION / N. Williams* - D. Ryan - A. Costa - L. O’Neill

P094 - ALVEOLAR MACROPHAGES SENSITIZED TO OXIDANTS AND LUNG VOLUMES OF THE INFLAMED LUNGS OF COPD AND SARCOIDOSIS PATIENTS / P. Jacobson* - L. Vainikka - H. L. Persson

P095 - CORONAVIRUS RNA IS CLEAVED BY RNASE L AND ENDOU TO REGULATE DOUBLE-STRANDED RNA ACTIVATED INNATE IMMUNE RESPONSES / R. Ancar* - Y. Li - E. Kindler - M. Ransom - D. Cooper - R. Silverman - V. Thiel - S. Weiss - J. R. Hesselberth - D. Barton

P096 INTERFERON-EPSILON IS A UNIQUE TYPE-I IFN PREDOMINANTLY EXPRESSED IN THE FEMALE REPRODUCTIVE TRACT THAT SUPRESSES ZIKV REPLICATION AND INTRAVAGINAL TRANSMISSION / R. C. Coldbeck-Shackley* - M. Tate - P. Hertzog - N. Eyre - K. Van der Hoek - M. Beard

P097 - HIGH RESOLUTION KINETIC CHARACTERIZATION OF THE RIG-I SIGNALING PATHWAY AND THE ENSUING ANTIVIRAL RESPONSES / S. Niesik* - D. Schweinoch - J. Frankish - C. Sparn - S. Wüst - J. Willemsen - L. Kaderali - M. Binder

P098 - GLOBAL 3’-UTR LENGTH CHANGES MEDIATED BY INTERFERON BETA IN MURINE AN HUMAN MACROPHAGES / S. Straub* - L. J. Gearing - S. C. Forster - D. J. Creek - K. Jeffrey - T. H. Beilharz - N. P. Croft - E. Latz - P. J. Hertzog

P099 - CX3CR1+ DENDRITIC CELLS ARE REQUIRED FOR REGULATION OF VIRAL ENCEPHALITIS THROUGH RAPID GENERATION OF NK AND T CELL RESPONSES IN PERIPHERAL LYMPHOID TISSUES / S. K. Eo* - J. Y. Choi - F. M. A. Hossain - E. Uyangaa - S. O. Park

P100 - TYPE I IFN-DEPENDENT CONCERTED RECRUITMENT OF MONOCYTES AND NK CELLS DURING MUCOSAL INFECTION WITH HERPES VIRUS / S. K. Eo* - E. Uyangaa - J. Y. Choi - S. O. Park

P101 - COLCHICINE REVERTS IL-1BETA RESPONSE IN MACROPHAGES INFECTED WITH MYCOBACTERIUM TUBERCULOSIS VIA PGE2–LTB4 AXIS / S. M. Kang* - K. W. Kwon - L.-H. Kim - E. Choi - S. J. Shin

P102 - TREM2 ON MICROGLIA IS REQUIRED FOR THE PHAGOCYTOSIS OF AB BY REGULATING C/EBP A-DEPENDENT CD36 EXPRESSION / S. M. Yee* - S. M. Kim - H. R. Choi - H. S. Kang

P103 - ZNF598 DELIVERS A UBIQUITIN-LIKE MODIFIER FAT10 TO RIG-I AND ATTENUATES THE INNATE IMMUNE RESPONSE AGAINST VIRAL INFECTION /T. Kouwaki* - H. Oshiumi

P104 - HYPOXIA INDUCES ENHANCEMENT OF INFLAMMASOME ACTIVATION BY P. GINGIVALIS INFECTION / T. Okano* - T. Suzuki

P105 - CHARACTERISING NEW INTERFERON: RECEPTOR INTERACTIONS AND THEIR IMPACT ON SIGNALING DIVERSITY / U.-S. Huang* - N. de Weerd - E. de Geus - N. Mangan - J. Volaric - P. Hertzog

P106 - MICROGLIAL TYPE I INTERFERON RESPONSE TO COMPLEX AMYLOID PROMOTES NEUROINFLAMMATION AND SYNAPSE LOSS IN ALZHEIMER’S DISEASE / E. Roy - B. Wang - Y.-W. Wan - O. Butovsky - H. Zheng - W. Cao*

P107 - TOLL-LIKE RECEPTOR 7 PLAYS A ROLE IN THE RECOVERY FROM EV71-INDUCED NEURAL IMPAIRMENTS / Y.-L. Lin* - C.-F. Chuang - H.-E. Lin - Y.-L. Kuo - S.-J. Lin - Y.-P. Hsueh - F. Liao

P109 - THE CONSERVED POLYBASIC RESIDUES IN THE CYTOSOLIC DOMAIN MEDIATES THE PLASMA MEMBRANE LOCALIZATION OF TLR5 / Y.-M. Kim* - J.-W. Huh - W. Kang - H. Song

P110 - REGULATION OF NON-CANONICAL INFLAMMASOME ACTIVATION BY XIAP / Y. H. Wu* - S. T. Mo - M. Z. Lai

P110A - DUSP4 REGULATES STING- AND RIG-I MEDIATED SIGNALING IN RESPONSE TO VIRAL INFECTION / Y. Zhang* - S. J. James

P110B - ZIKA VIRUS NS5 PROTEIN AND INNATE IMMUNITY / M. T. Sanchez-Aparicio* - A. Garcia-Sastre

P110C - IL-1BETA PRODUCED BY NLRP3 INFLAMMASOME IN TUMOR MICROENVIRONMENT PROMOTES THE METASTATIC POTENTIAL OF CANCER / J. Y. Lee* - H. E. Lee - J. Y. Lee - G. Yang - H. C. Kang - Y-Y. Cho - H. S. Lee

MUSOCAL IMMUNITYHighlighted posters will part of a poster tour

chaired by Mariana Kaplan (US)

P111 - BERBERIS LYCIUM FRUIT EXTRACT MAINTAINS INTESTINAL HOMEOSTASIS IN DEXTRAN SULPHATE SODIUM INDUCED COLITIS BY MITIGATING NF-KB/C-JUN/MAPKS SIGNALING CASCADE AND ENHANCING TREGS IN SPLENIC LYMPHOCYTES / A. Sharma* - N. V. Tirpude - R. Sharma - Y. S. Padwad

P112 - MICROBIOTA-DRIVEN TONIC INTERFERON SIGNALS IN LUNG STROMAL CELLS PROTECT FROM INFLUENZA VIRUS INFECTION / A. Wack*

P113 - CONTEXT-DEPENDENT REGULATION OF MRNA DECAY AND ITS FUNCTIONAL CONSEQUENCES / A. Bestehorn* - F. Ebner - P. Kovarik

P114 - TYPE I AND III INTERFERONS (IFNS) INDUCE DIFFERENTIAL DYNAMICS OF IFN-STIMULATED GENE FACTOR (ISGF3) ACTIVITY / C. L. Wilder* - Q. J. Cheng - S. Mitchell - A. Meyer - A. Hoffmann

P116 - IFN-LAMBDA SIGNALING UNIQUELY REGULATES DENDRITIC CELL FUNCTION TO ORCHESTRATE T CELL IMMUNITY DURING INFLUENZA A VIRUS INFECTION / E. A. Hemann* - R. Green - R. A. Langlois - R. Savan - M. Gale

30


P117 - GEF-H1 IS ESSENTIAL FOR INTESTINAL ANTIVIRAL IMMUNITY BY REGULATING INTERFERON-LAMBDA EXPRESSION / Y.-C. Peng - Y.-C. Chen - F. Hsin - H.-S. Chiang*

P119 - EFFECT OF ANTIBIOTIC-INDUCED CHANGES IN MICROBIOTA ON REGULATORY T CELLS IN MUC2-/- MICE / K. Achasova* - E. Kozhevnikova - M. Borisova - E. Litvinova

P121 - IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ABCF1 IN HUMAN AIRWAY EPITHELIAL CELLS IN RESPONSE TO VIRAL STIMULI / Q. T. Cao* - N. Abbas - J. Aguiar - A. Doxey - K. Ask - J. A. Hirota

P122 - INDUCTION OF LUNG TOLERANCE BY INTERFERON-B: A PROMISING THERAPEUTIC TREATMENT FOR ASTHMA / S. Mansouri* - D. S. Katikaneni - H. Gogoi - M. Pipkin - T. N. Machuca - A. M. Emtiazjoo - L. Jin

P123 - THE INTESTINE HARBOURS FUNCTIONALLY DISTINCT HOMEOSTATIC TISSUE-RESIDENT AND INFLAMMATORY TH17 CELLS / S. Omenetti* - C. Bussi - A. Metidji - A. Iseppon - S. Lee - M. Tolaini - Y. Li - G. Kelly - P. Chakravarty - S. Shoaie - M. Gutierrez - B. Stockinger

P124 - FUNCTIONAL MODELING OF THE RARE HUMAN DISEASE DITRA UNVEILS NOVEL ROLE OF IL-36R AXIS IN INTESTINAL INFLAMMATION / S. Haxhinasto* - Z. Hovhannisyan on behalf of Regeneron Pharmaceuticals

P125 - CELIAC DISEASE IN CHILDREN, PARTICULARLY WITH ACCOMPANYING TYPE 1 DIABETES, IS CHARACTERIZED BY SUBSTANTIAL CHANGES IN THE BLOOD CYTOKINE BALANCE, WHICH MAY REFLECT INFLAMMATORY PROCESSES IN THE SMALL INTESTINAL MUCOSA / T. Vorobjova* - A. Tagoma - A. Oras - K. Alnek - K. Kisand - I. Talja - O. Uibo - R. Uibo

P125A - CD103HI TREG CELLS REGULATE LUNG FIBROTIC RESPONSE INDUCED BY CD103LO TISSUE-RESIDENT PATHOGENIC CD4 T CELLS / K. Hirahara* - T. Ichikawa - K. Kokubo - T. Nakayama

P125B - THE ROLE OF IL-17A IN CHRONIC RHINOSINUSITIS WITH NASAL POLYP / G. Ryu* - J-S. Bae - J. H. Kim - E. H. Kim - Y-J. Chung - J-H. Mo

P125C - DIFFERENTIAL CYTOKINE EFFECTS ON INTESTINAL STROMAL CELLS UNDERLIE PATHOGENIC TISSUE SIGNATURES IN INFLAMMATORY BOWEL DISEASE / M. Friedrich* - M. Pohin - M. Jackson - S. Bullers - Z. Christoforidou - K. Rue-Albrecht - S. Sansom - F. Powrie

P125D - IL-17A/F1 DEFICIENCY DWON-REGULATES IMMUNE-RELATED GENE EXPRESSION AND CHANGES TO INTESTINAL FLORA IN JAPANESE MEDAKA (ORYZIAS LATIPES) / M. Sakai* - Y. Okamura - N. Morimoto - T. Kono - J-I Hikima

P125E - REDUCED HISTONE DEACETYLASE ACTIVITY SUPPORTS A LESS INFLAMMATORY VAGINAL MILIEU, UNFAVORABLE FOR THE ESTABLISHMENT OF HIV-INFECTION / C. Card - A. Sivro - J. Schellenberg - J. Kimani - F. A. Plummer - T. B. Ball - R-C. Su*

T CELL DIFFERENCIATION AND FUNCTIONHighlighted posters will part of a poster tour

chaired by Ari Waisman (DE)

P126 - THE MOLECULAR BASIS OF HEPATITIS B VACCINE NON-RESPONSIVENESS / A. Ziegler* - M. Bruhn - M. Uthe - M. Redlich - V. von Bülow - M. Verboom - M. Wiestler - M. Hallensleben - C. Davenport - L. Wiehlmann - S. Zimmermann-Schriek - T. Rebe - M. Cornberg - C. Falk - U. Kalinke

P130 - SENESCENCE-ASSOCIATED B-GALACTOSIDASE ACTIVITY AND OTHER MARKERS OF SENESCENCE IN HUMAN PERIPHERAL BLOOD IMMUNE CELLS DURING HEALTHY AGING AND HIV-INFECTION / H. K. Dewald* - R. I. Martínez-Zamudio, - T. Vasilopoulos - S. Swaminathan - U. Herbig - P. Fitzgerald-Bocarsly

P131 - CD8+ T CELLS INDUCE CACHEXIA DURING CHRONIC VIRAL INFECTION / H. Baazim* - M. Schweiger - M. Moschinger - H. Xu - T. Scherer - A. Popa - S. Gallage - A. Ali - K. Khamina - L. Kosack - B. Vilagos - M. Smyth - A. Lercher - J. Friske - D. Merkler - A. Aderem - T. H. Helbich - M. Heikenwälder - P. A. Lang - R. Zechner - A. Bergthaler

P132 - IDENTIFICATION OF IMMUNOMETABOLITES THAT SHAPE THE ADAPTIVE ANTIVIRAL IMMUNE RESPONSE / J.-W. Genger* - A. Bergthaler

P133 - PROTOCOLS FOR IN VITRO ACTIVATION, POLARIZATION AND EVALUATION OF CD4+ T CELL LINEAGES / C. Yu - D. Yu - H. Soto - J. Love - B. Sun - S. Ji - W. Jiang - J. Zhou*

P134 - RECOMBINANT MOUSE IL-2 AND ANTI-MOUSE IL-2 ANTIBODY COMPLEX INDUCES T REGULATORY CELLS IN VIVO / H. Soto - J. Moyron-Quiroz - Z. R. Moya - M. Tam - J. Love - X. Yang - D. Nguyen - J. Zhou*

P135 - ANTIBODIES TARGETING THREE DIFFERENT DOMAINS OF S PROTEIN EXHIBIT HIGHLY POTENT NEUTRALIZING ABILITY AGAINST PSEUDOTYPED MERS-COV / J. Kim* - Y. S. Choi

P136 PROPOLIS MAY AFFECT HUMAN CD4+ T CELLS DIFFERENTIATION INDUCED BY MAGE-1-TREATED DENDRITIC CELLS / K. B. Santiago* - E. O. Cardoso - B. J. Conti - F. L. Conte - L. P. G. Oliveira - K. I. Tasca - G. G. Romagnoli - M. A. Golim - M. T. Cruz - J. M. Sforcin

P137 - PERIPHERAL BLOOD LYMPHOCYTE SUBSETS INCLUDING REGULATORY T CELL IN BREAST CANCER PATIENTS UNDER TREATMENT / K.-H. Shin* - H.-J. Lee - S. Yu

P139 - NK CELL RECEPTOR NKG2D ENFORCES PRO-INFLAMMATORY FEATURES AND PATHOGENICITY OF TH1 AND TH17 CELLS / M. Babic Cac* - C. Dimitropoulos - C. Stehle - F. Heinrich - Q. Hammer - B. Polic - C. Romagnani

P140 - CD29 EXPRESSION ON HUMAN T CELLS SELECTS FOR CELLS WITH A HIGH CYTOTOXIC PROFILE / B. Nicolet - A. Guislain - F. van Alphen - R. Gomez-Eerland - T. Schumacher - M. van den Biggelaar - M. C. Wolkers*

P141 - CYTOKINE PRODUCTION BY TH2 CELLS IS REGULATED BY SODIUM AND GLUCOSE / P. Cochez* - M. De Heusch - E. Hendrickx - P. Cheou - J.-C. Renauld - L. Dumoutier

31

P143 - ENDOGENOUS N-3 POLYUNSATURATED FATTY ACIDS ARE BENEFICIAL TO DAMPEN INFLAMMATORY RESPONSE MEDIATED BY CD8+ T CELLS AGAINST THE VIRAL INFECTION / S.-M. Lee* - Y.-J. Seo - K.-W. Kang - S. Kim - Y.-B. Cho

P144 - SPECIFIC TARGETING OF IL-1B ACTIVITY TO CD8+ T CELLS MOUNTS A STRONG CELLULAR ANTIGEN-SPECIFIC IMMUNE RESPONSE AND COMPLETELY PROTECTS AGAINST INFLUENZA INFECTION IN MICE / B. Van Den Eeckhout - L. Van Hoecke - E. Burg - S. Van Lint - F. Peelman - X. Saelens - J. Tavernier - S. Gerlo*

P145A - TRANSCRIPTION FACTOR P73 REGULATES TH1 DIFFERENTIATION / M. Ren* - M. Kazemian - M. Zheng - P. Li - J. Oh - W. Liao - G. Pelt - W. J. Leonard

P145B - T CELL INTRINSIC NLRP3-INFLAMMASOME ACTIVATION PROMOTES HUMAN TH17 CELL PATHOGENICITY THROUGH IL-1A BUT NOT IL-1B PRODUCTION / C. Zielinski* - Y-Y. Chao

P145C - ELUCIDATING THE MECHANISM OF AITL ONCOGENESIS BY ANALYZING CHARACTERISTICS OF INTRATUMORAL FOLLICULAR HELPER T CELLS / K. C. Han* - Y. S. Choi

P145D - DC-TARGETED VACCINATION USING THE NONTOXIC CHOLERA B SUBUNIT AS AN ADJUVANT INDUCES LONG-TERM LOCAL AND SYSTEMIC TH1 AND TH17 PROTECTIVE IMMUNE RESPONSES / L. A. Herrera* - O. B. Godinez - O. M. Contreras - A. T. Segura - A. G. Lozano - L. G. Xicotencatl - G. Soldevilla - F. Esquivel - J. Idoyaga - L. Bonifaz

P145E - DYNAMIC PROTEIN LANDSCAPE DURING INITIATION OF HUMAN TH17 CELL DIFFERENTIATION / S. K. Tripathi*

P145F - THE ROLE OF IL-1R SIGNALING IN DIFFERENTIATION AND FUNCTION OF TH17 CELLS / W. Miller-Little* - X. Li


Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research

ICIS BioLegend William E. Paul Award

The Sidney & Joan Pestka Graduate & Post-Graduate Awards for Excellence in Interferon and Cytokine Research

The Christina Fleischmann Award to Young Women Investigators

Other ICIS Awards

The preeminent Seymour & Vivian Milstein Award for Excellence

in Interferon and Cytokine Research, commonly known as

The Milstein Award, recognizes individuals who have made

exceptional contributions to interferon and cytokine research,

either in a basic or applied field. Many of these achievements

have led to the advancement of human health. Award:

$10,000 from the Milstein Family Grant. ICIS Crystal and travel

reimbursement from ICIS as well as meeting registration waived

for the year of the Award. Oral presentation at the Annual Meeting

of the International Cytokine & Interferon Society, Cytokines 2020,

1-4 November in Seattle, USA. www.seattle.cytokinesociety.org.

The Milstein family also supports The Milstein Young Investigator

Awards and The Milstein Travel Awards for ICIS members

presenting abstracts at Cytokines 2020.

This prestigious award is given to an investigator that has made

significant contributions to cytokine and interferon research

throughout their career. Through the generosity of BioLegend

the award consists of $2500, ICIS Crystal (3 D structure of IL-4),

travel reimbursement and meeting registration waived for the

year of the Award. Oral presentation at Cytokines 2020.

These awards are targeted to graduate students and post-

doctoral fellows who have begun to make an impact in interferon

and cytokine research. The Awards are designed to fill the

gap among the awards currently offered by the ICIS to more

senior investigators. Candidates must be actively working in

interferon/cytokine research. Each award includes a $3500

cash award, $1500 travel grant to attend Cytokines 2020, a

$2500 PBL Assay Science product credit for each awardee, and

a complimentary one-year ICIS membership.

This award is open to young women investigators working

in the cytokine, chemokine and interferon biology, thanks to

the generosity of the Fleischmann Foundation in memory of

outstanding interferon research scientist Christina Fleischmann.

The award includes a $2000 cash award through a grant from

the Fleischmann Family Fund.

› Honorary Lifetime Membership Award

› Distinguished Service Award

› Milstein Travel Awards

› Milstein Young Investigator Awards

Sponsored by:

Presented by:

ANNUAL AWARDSNOMINATION/SUBMISSION DEADLINES:

› 5 March 2020: The Milstein Award and the ICIS-BioLegend William E. Paul Award› 17 April 2020: Honorary Lifetime Membership & Distinguished Service Awards› 15 May 2020: All Young Investigator Awards› 1 June 2020: Milstein Travel Awards

More information/submission site: https://cytokinesociety.org/awards/

www.milstein-award.org

Milstein Young Investigator Awards

2019ICIS Award

Winners

Juan Luis Mendoza, Ph.D.

Assistant ProfessorThe University of Chicago,

Chicago, USA

Juan Fuxman Bass, Ph.D.

Assistant Professor of BiologyBoston University,

Boston, USA

Sarah Doyle Ph.D.

Assistant Professor in Immunology, Dept. Clinical Medicine, School of Medicine, Trinity College Dublin,

Dublin, Ireland

Ryan A. Langlois, Ph.D.

Assistant Professor, Dept of Microbiology & Immunology,

University of MinnesotaMinneapolis, USA

Yuxin Wang, Ph.D.

Research AssociateLerner Research Institute,

Cleveland Clinic, Cleveland, USA

ICIS Honorary Lifetime Membership

Award

ICISDistinguished

Service Award

The Seymour & Vivian Milstein Award for Excellence in Interferon & Cytokine

Research

ICIS-BioLegend William E. Paul Award

for Excellence in Cytokine Research

Hao Wu, Ph.D.

Asa and Patricia Springer Professor of Structural Biology,

Department of Biological Chemistry and Molecular

Pharmacology, Harvard Medical School, and Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, USA

Akiko Iwasaki, Ph.D.

Waldemar Von Zedtwitz Professor of Immunobiology;

Molecular, Cellular and Developmental Biology; and Dermatology; Investigator, Howard Hughes Medical

Institute, Yale University, New Haven, USA

Chen Dong, Ph.D.

Professor and Director of the Institute for Immunology and

Dean of the School of Medicine, Tsinghua University,

Beijing, China

Bryan R.G. Williams, Ph.D., Hon. FRSNZ, FAA

Hudson Institute of Medical Research, Clayton, Australia

Kouji Matsushima, MD, Ph.D.

Division of Molecular Regulation of Inflammatory and Immune

Diseases, Research Institute for Biomedical Sciences, Tokyo

University of Science, Chiba, Japan

The Sidney & Joan Pestka Graduate & Post Graduate Awards for Excellence in Interferon and Cytokine Research – sponsored by PBL Assay Science

The Christina Fleischmann Award to Young Women Investigators

Meike Dittmann, Ph.D.

Assistant Professor Department of Microbiology

New York University School of Medicine, New York, NY, USA

Anukriti Mathur

PhD candidate, Department of Immunology and Infectious Disease, The John Curtin

School of Medical Research, Australian National University,

Canberra, Australia

Graduate

Billur Akkaya, MD, D.Phil

Research Fellow, Laboratory of Immune System Biology, National Institute of Allergy

and Infectious Diseases, National Institutes of Health,

Bethesda, USA

Post-Graduate

34

Poster Session 2 - Tuesday 22 October

P162 - BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSION / R. Hoffman* - Y. Tanaka - T. Dörner - M. Petri - J. S. Smolen - E. R. Dow - R. E. Higgs - G. Rocha - R. J. Benschop - M. E. Silk - S. de Bono

P163 - CHARACTERIZATION OF RENAL INFLAMMATION IN THE TRANSGENIC MICE WITH HUMAN RIG-I SMS VARIANT / S. Satoh* - A. A. Tayeh - F. L. Emralino - T. Ohto - M. Funabiki - H. Kato - T. Fujita

P165 - IRF5 SUPPRESSION EXERTS A THERAPEUTIC EFFECT BEYOND TYPE I INTERFERON BLOCKADE ON MURINE SLE / T. Ban* - M. Kikuchi - G. R. Sato - A. Manabe - N. Tagata - K. Nishimura - R. Yoshimi - Y. Kirino - H. Yanai - Y. Matsumoto - H. Hihara - M. Ito - K. Tsukahara - T. Taniguchi - H. Nakajima - S. Ito - T. Tamura

P165A - TWO COMMON DISEASE-ASSOCIATED TYK2 VARIANTS IMPACT EXON SPLICING AND TYK2 DOSAGE / Z. Li* - M. Rotival - E Patin - F. Michel - S. Pellegrini

P165B - TREM-2 MEDIATES MSU-INDUCED NALP3 INFLAMMASOME ACTIVATION AND IL-1 BETA INDUCTION THROUGH A PKC DELTA-DEPENDENT SIGNALING / N-J. Chen*

P165C - TRISOMY 21 DYSREGULATES THE HUMAN PERIPHERAL T CELL COMPARTMENT TOWARD A STATE ASSOCIATED WITH CHRONIC INFLAMMATION AND AUTOIMMUNITY / P. Araya* - K. A. Waugh - K. D. Sullivan - N. G. Nuñez - E. Roselli - K. P. Smith - R. E. Granrath - A. L. Rachubinski - E. T. Butcher - R. Minter - K. D. Tuttle - T. C. Bruno - M. Maccioni - J. M. Espinosa

CYTOKINE REGULATIONHighlighted posters will part of a poster tour

chaired by Stefan Rose-John (DE)

P166 - ANTI-INFLAMMATORY FUNCTIONS OF GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS THROUGH EPIGENETIC AND TRANSCRIPTIONAL REGULATION OF CCL17 PRODUCTION / A. Achuthan* - T. Lupancu - M.-C. Lee - A. Fleetwood - A. Cook - J. Hamilton

P167 - RECONSTITUTING THE HUMAN JAK/STAT PATHWAY INTO DROSOPHILA S2 CELLS / A. L. McFarlane* - I. Moraga-Gonzalez

P168 - TYROSINE KINASE 2 (TYK2) IS CRITICAL FOR THE INDUCTION OF CASPASE-11 AND NON-CANONICAL INFLAMMASOME-DEPENDENT IL-1BETA AND IL-18 PRODUCTION DURING ENDOTOXEMIA / A. Poelzl* - C. Lassnig - S. Tangermann - S. Macho-Maschler - U. Reichart - R. Gawish - L. Kenner - M. Mueller - B. Strobl

P169 - IFN-BETA THERAPY IN MULTIPLE SCLEROSIS CHANGES THE RESPONSES TO IL-6, IL-10, AND IFN-GAMMA DIFFERENTLY IN CD4+ T CELLS AND ANTIGEN PRESENTING CELLS OF GOOD AND POOR RESPONDERS: IMPLICATIONS FOR REGULATORY CD4+ T CELL DEVELOPMENT / A. Landrigan - H. van Houwelingen - J. Killestein - R. Fox - G. R. Stark - A. H. H. Van Boxel-Dezaire*

AUTOINFLAMMATION AND AUTOIMMUNITYHighlighted posters will part of a poster tour

chaired by Georg Schett (DE)

P146 - HYPOXIA RESISTANT PATHOGENIC B CELLS ACCUMULATE IN THE RA SYNOVIAL TISSUE IN A CXCR3 DEPENDENT MANNER / A. Floudas* - C. Low - M. Biniecka - D. J. Veale - U. Fearon

P147 - INDUCIBLE MALT1 PROTEASE–DEFICIENT MICE: A MOUSE MODEL TO STUDY THE SAFETY OF MALT1 PROTEASE INHIBITION / A. Demeyer* - Y. Driege - J. Staal - R. Beyaert

P148 IL-17 DRIVES THE RECRUITMENT OF IL-1B-PRODUCING INNATE CELLS THAT PROMOTE THE DEVELOPMENT OF IL-17-SECRETING γδ T CELLS AND TH17 CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY / A. Mc Ginley* - C. Sutton - S. Edwards - K. Mills

P149 - IRF5 GENETIC RISK VARIANTS DRIVE MYELOID-SPECIFIC IRF5 HYPER-ACTIVATION AND PRE-SYMPTOMATIC SLE / D. Li - B. Matta - S. Song - B. Barnes*

P150 - ACCUMULATIVE DEFECTS IN IRF5 KNOCKOUT B AND T CELLS CONTRIBUTE TO THE DEFECTIVE GENERATION OF ANTIBODY SECRETING CELLS / B. Matta* - Q. Guo - B. Barnes

P152 - KINASE-DEPENDENT AND -INDEPENDENT FUNCTIONS OF TYROSINE KINASE 2 (TYK2) DURING CONCANAVALIN A-INDUCED HEPATITIS / D. Gogova* - A. Puga - C. Lassnig - S. Macho-Maschler - U. Reichart - M. Müller - B. Strobl

P153 - EXPANDED ANTIGEN-SPECIFIC T CELL NUMBERS IN INTERFERON-RECEPTOR DEFICIENT NON-OBESE DIABETIC MICE / H. Thomas* - T. Brodnicki - S. Akazawa - G. Jhala - B. Krishnamurthy - T. Kay

P154 - IL-27 LEVEL IS INCREASED DURING OCULAR MANIFESTATIONS ASSOCIATED WITH BEHÇET DISEASE / H. Belguendouz* - K. Lahmar - A. Chekaoui - L. M. Ahmedi - M. Terahi - D. Hakem - C. Touil-Boukoffa

P156 - CUTANEOUS AND SYNOVIO-ENTHESEAL INFLAMMATION IN A NOVEL MODEL OF PSORIATIC ARTHRITIS / K. L. Yang*

P157 - UNDERSTANDING DOWN SYNDROME AS AND INTERFERON-DRIVEN IMMUNE DISORDER / K. D. Tuttle - K. A. Waugh - R. K. Powers - K. P. Smith - R. Granrath - R. Minter - A. Rachubinski - J. M. Espinosa - K. D. Sullivan*

P158 - RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND INFLAMMATION IN PERIPHERAL JOINTS AND ENTHESES IN AXIAL SPONDYLOARTHRITIS / K. Y. Kang* - Y. S. Hong

P159 - CHARACTERIZING THE PLASMA AND JOINT FLUID CYTOKINE PROFILE IN END STAGE KNEE OSTEOARTHRITIS AND THE CYTOKINE RESPONSE TO TOTAL KNEE ARTHROPLASTY / M. Kirksey* - G. Birch - H. Zhong - A. Sideris - V. Rotundo - K. Jules

P161 - SINGLETON-MERTEN SYNDROME-LIKE SKELETAL ABNORMALITIES IN MICE WITH CONSTITUTIVELY ACTIVATED MDA5 / N. Soda* - N. Sakai - H. Kato - M. Takami - T. Fujita

35

P170 - IDENTIFICATION OF RNA BINDING PROTEINS THAT MODULATE THE CYTOKINE PRODUCTION OF HUMAN T CELLS / B. Popovic* - F. Salerno - B. P. Nicolet - J. J. Freen-van Heeren - S. Engels - A. Guislain - F. van Alphen - M. van den Biggelaar - M. C. Wolkers

P171 - ONCOSTATIN M MODULATES WNT SIGNALING IN THE LUNGS OF C57BL/6 MICE / F. Botelho - A. Dvorkin - D. Bridgewater - C. D. Richards*

P172 - CRANIOSYNOSTOSIS-ASSOCIATED IL11RA MUTATIONS HAVE DIVERGENT EFFECTS ON THE INTERLEUKIN-11 RECEPTOR / C. Garbers* - M. Agthe - B. Kespohl - J. Lokau

P173 - DIFFERENTIAL ENHANCER USAGE DETERMINES STAT INVOLVEMENT IN PERITONEAL INFLAMMATION AND FIBROSIS / D. Millrine* - J. Uceda-Fernandez - A. Cardus-Figueras - G. Jones - N. Williams - D. Fraser -S. Jones

P174 - CLOCK DEPENDENT IL1B AUTO-REGULATORY LOOP REGULATES INFLAMMATION IN GLIOMA / E. Sen* - P. Gowda - K. Lathoria - S. Sharma

P175 - DETERMINING THE ROLE OF MICROGLIA AND ASTROCYTES IN CEREBRAL TYPE I INTERFERONOPATHIES / E. Hayashida* - B. Viengkhou - M. J. Hofer

P176 - IL-22 TRIGGERS A SUBPOPULATION OF MACROPHAGE INFILTRATION EXPRESSING DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES INTO ADIPOSE TISSUE DISPLAYING FUNCTIONAL PHENOTYPES OF M2-LIKE MACROPHAGE / E. Y. Kim - J. E. Kim - B. Choi - H. K. Lee - Y. G. Kim - E. J. Chang*

P177 - CYTOKINE-SENSING ENHANCERS LAUNCH SECONDARY ENHANCERS TO ACTIVATE MULTI-GENE LOCUS / H. K. Lee* - L. Hennighausen

P178 - A20 IN MYELOID CELLS REGULATES IL-33-INDUCED LUNG INFLAMMATION / I. Afonina* - A. Holgado - M. Haegman - R. Beyaert

P179 - A NEW GM-CSF-DRIVEN PATHWAY IN INFLAMMATION AND PAIN / J. A. Hamilton* - A. D. Cook - M.-C. Lee - R. Saleh - A. Achuthan

P180 - DETERMINANTS OF IL-11 RECEPTOR PROTEOLYSIS / J. Lokau* - L. Koch - M. Agthe - C. Garbers

P182 - PHYSIOLOGY AND MECHANISM OF INTERLEUKIN-1 SIGNALING REGULATION BY TRISTETRAPROLIN / L. Sneezum* - P. Kovarik

P183 - IDENTIFICATION OF IL-18BP-PRODUCING CELLS IN A MODEL OF MACROPHAGE ACTIVATION SYNDROME / M. Harel* - E. Rodriguez - C. Girard-Guyonvarc’h - G. Palmer - C. Gabay

P184 - GM-CSF- AND IRF4-DEPENDENT SIGNALING IN MACROPHAGES ELEVATES CCL17 PRODUCTION REQUIRED FOR ZYMOSAN-INDUCED ARTHRITIS / M.-C. Lee* - A. Fleetwood - A. Achuthan - J. Hamilton - A. Cook

P186 - CD28 RECEPTOR DIMER INTERFACE CONTROLS B7 COLIGAND ENGAGEMENT AND SIGNALING FOR PRO-INFLAMMATORY CYTOKINE EXPRESSION / R. Kaempfer* - Z. Rotfogel - A. Popugailo - M. Levy - O. Turgeman - D. L. Barnard


P187 - ORAL ADMINISTRATION OF PHYTOCANNABINOID B-CARYOPHYLLENE INCREASE SERUM ADIPONECTIN LEVELS WICH CORRELATES WITH IMPROVEMENT IN DEPRESSION-ASSOCIATED BEHAVIOR IN A MURINE MODEL OF OBESITY / R. I. Lopez* - N. N. Franco-Arroyo - J. M. Viveros-Paredes - A. M. Sanchez-Sanchez - K. Sanchez-Reyes

P189 - COMPUTER MODEL OF A GATEWAY OF IMMUNE CELLS ACROSS BLOOD-BRAIN BARRIER / S. Yamada* - A. Yoshimura - D. Kamimura - M. Murakami

P190 - INTERLEUKIN-17D PROMOTES PATHOGENICITY DURING INFECTION BY SUPPRESSING CD8 T CELL ACTIVITY / S. H. Chang* - Y. Lee - J. Clinton - C. Yao

P191 - INVESTIGATING KINASE-DEPENDENT AND -INDEPENDENT FUNCTIONS OF TYK2 IN DENDRITIC CELLS / S. Shoebridge* - K. Meissl - M. Krunic - S. Macho-Maschler - A. Pölzl - M. Farlik - N. Fortelny - C. Bock - M. Dolezal - F. Ruge - C. Lassnig - B. Strobl - M. Müller

P192 - TELMISARTAN, AN ANGIOTENSIN II RECEPTOR BLOCKER, ATTENUATES PREVOTELLA INTERMEDIA LIPOPOLYSACCHARIDE-INDUCED PRODUCTION OF NITRIC OXIDE AND INTERLEUKIN-1B IN MURINE MACROPHAGES / S.-J. Kim* - S.-H. Choe - E.-Y. Choi - J.-Y. Hyeon - B. R. Keum - I. S. Choi

P193 - INTERLEUKIN 4 UP-REGULATES GLUCOSE UPTAKE IN ADIPOCYTES BY INSULIN-INDEPENDENT MECHANISMS AND PREVENTS DEVELOPMENT OF LIPID-INDUCED INSULIN RESISTANCE / S. Michurina* - I. Stafeev - I. Beloglazova - Y. Molokotina - E. Zubkova - E. Shevchenko - A. Vorotnikov - M. Menshikov - Y. Parfyonova

CYTOKINES IN ALLERGY AND TH2 IMMUNITY

P195 - EFFECT OF IL-33 TARGETING IN A. ALTERNATA-INDUCED ALLERGIC AIRWAY INFLAMMATION USING A NEWLY DEVELOPED IL-33 ANTAGONIST / A. Holgado* - R. Beyaert - I. Afonina - H. Braun

P199 - USING THE INVITROGEN PROQUANTUM HIGH-SENSITIVITY IMMUNOASSAY PLATFORM FOR TEMPORAL PROFILING OF TYPE 2 AIRWAY INFLAMMATION MARKERS IN NASAL MUCOSAL LINING FLUID / M. Miholits* - H. Ekoff - R. S. Thwaites - N. Singh - A. Sjölander - T. Hansel - D. Bourdon - M. Molin

P200 - DISTINCT EXPRESSION OF DENDRITIC CELL SUBSETS IN NASAL MUCOSA OF PATIENTS WITH ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS / S. C. Park* - Y. Bak - S. J. Shin - J.-H. Yoon - C.-H. Kim

P201 - DEVELOPMENT AND CHARACTERIZATION OF AN EXACERBATED MURINE ASTHMA MODEL ACCOMPANYING BY SIMULTANEOUS TH2/TH17-SKEWED RESPONSES VIA INTRAVENOUS TRANSFER OF ALLERGEN-LOADED DENDRITIC CELLS / S. C. Park - H. Kim - Y. Bak - K. W. Kwon - D. Shim - C.-H. Kim - J.-H. Yoon - S. J. Shin*

P202 - UNEXPECTED ROLE OF FMS-LIKE TYROSINE KINASE 3-INDEPENDENT DENDRITIC CELLS IN ALLERGIC ASTHMA IN MICE / S. C. Park - D. Shim - H. Kim - Y. Bak - J.-H. Yoon - C.-H. Kim - S. J. Shin*

36


P212 - HETERODIMERIC IL-15 SHAPES THE TUMOR CYTOKINE AND CHEMOKINE MILIEU, PROMOTING MYELOID-LYMPHOID CELLS INTERACTIONS AND IMMUNE CELL RECRUITMENTS INTO THE TUMORS / C. Bergamaschi* - D. Stellas - S. Karaliota - B. Nagy - S. M. Jensen - B. Fox - K. Dimas - B. K. Felber - G. N. Pavlakis

P213 - THE BALANCE OF STAT3 ISOFORMS IS ESSENTIAL IN ACUTE MYELOID LEUKEMIA / P. Aigner - T. Mizutani - J. Horvath - V. Just - H. Sill - F. Grebien - R. Moriggl - E. Casanova - D. Stoiber*

P214 - THERAPEUTIC BLOCKADE OF TGF-BETA SUPERFAMILY MEMBERS IMPROVES NATURAL KILLER CELL FUNCTION AND ANTI-TUMOR IMMUNITY / F. Guimaraes* - J. Cursons - J. Rautela - L. Dagley - N. Huntington

P216 - THE MULTI-SITE DOCKING PROTEIN GAB1 AND ITS ROLE IN BREAST CANCER / H. Bongartz* - F. Schaper

P217 - TARGETING STAT5 AS A DRIVER IN PERIPHERAL T CELL LEUKEMIA/LYMPHOMA AND COOPERATING CANCER PATHWAYS / H. Sorger* - A. Orlova - H. A. Neubauer - M. Herling - P. T. Gunning - R. Moriggl

P219 - CXCL13 PLASMA LEVELS FUNCTION AS A BIOMARKER FOR DISEASE ACTIVITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA / J. Burger* - M. Sivina

P224 - UNRAVELLING THE FULL PATHOPHYSIOLOGICAL SUBSTRATE REPERTOIRE OF THE ADAM17 PROTEASE / M. Saad* - J. J. Balic - A. West - S. Rose-John - B. J. Jenkins

P225 - TYPE I INTERFERON MEDIATED REGULATION OF LIVER COLORECTAL CANCER METASTATIC SPREADING / N. L. Tran* - L. M. Ferreira - V. Buttiglione - A. Monestiroli - C. Fagioli - F. Ratti - C. Stambazzi - L. Aldrighetti - F. Pedica - C. Doglioni - A. Spinelli - P. Marra - L. G. Guidotti - G. Sitia

P226 - STAT5A AND STAT5B IN HEMATOPOIETIC AND LEUKEMIC STEM CELLS – BETWEEN DEATH AND IMMORTALITY / S. Kollmann* - M. Prchal-Murphy - B. Maurer - M. Farlik - V. SexlP227 - ADIPONECTIN DEFICIENCY SUPPRESSES LYMPHOMA GROWTH IN MICE BY MODULATING NK CELLS, CD8 T CELLS, AND MYELOID-DERIVED SUPPRESSOR CELLS / S. Han* - Y. Yang

P228 - STAT3 ANTI-INFLAMMATORY ACTIVITY IN DENDRITIC CELLS MODULATES IMMUNE-MEDIATED ADVERSE EVENTS DURING CTLA-4 BLOCKADE / S. Watowich* - Y. Zhou - Y. Medik - R. Babcock - T. T. Chrisikos - B. Patel - K. Newton - L. K. Serrudo - X. Wan - H. S. Li

P229 - IN VIVO LOSS OF IRF5 RESULTS IN SPONTANEOUS MAMMARY TUMORIGENESIS BY ALTERING METABOLISM AND GLOBAL MRNA TRANSLATION IN MAMMARY EPITHELIAL CELLS / S. Song* - D. Li - K. Kampta - M. Lapan - Q. Guo - B. Barnes

P230 - ESTROGEN RECEPTORS REGULATE THE WNT/B-CATENIN SIGNALING PATHWAY IN CANCER BY TARGETING THE NOD-LIKE RECEPTORS / S. Song* - C. Ding - S. Liu

P203 - THERAPEUTIC EFFECTS OF RIFAMPICIN ON ATOPIC DISEASES, ATOPIC DERMATITIS AND ASTHMA, IN VIVO AND IN VITRO / T. J. Kang* - Y. R. Kim - K. J. Boo - J. W. Park - A. V. Prakash - J. Seong

P204 - INVESTIGATION ON THE PATHOGENESIS OF PULMONARY COMORBIDITY ACCOMPANIED BY BOTH CHRONIC DISEASES, ASTHMA AND NONTUBERCULOUS MYCOBACTERIAL INFECTION, IN A MURINE MODEL / Y. Bak* - S. C. Park - D. Shim - Y. Ha - S. J. Shin

P204A - DETERMINATION OF INTERFERONS AND BIOMARKERS IN INFLUENZA DONOR SAMPLES / B. Schwartz - G. Kisiel - A. Panday - K. Skup - W. Clark - T. Lavoie*

P204C - THERAPEUTIC EFFECT OF TOPICAL ADMINISTRATION OF RED ONION EXTRACT IN A MURINE MODEL OF ALLERGIC RHINITIS / M. Y. Seo* - H. Y. Kim

CYTOKINES IN CANCER DEVLOPMENT AND ANTITUMOR IMMUNE THERAPY

Highlighted posters will part of a poster tourchaired by Brendan Jenkins (AU)

P205 - TYK2 IMPACTS ON TRANSCRIPTIONAL AND EPIGENOMIC PROFILES IN IMMUNE CELLS / A. Karjalainen* - M. Krunic - K. Meissl - S. Macho-Maschler - A. Pölzl - M. Farlik - N. Fortelny - M. Dolezal - F. Ruge - C. Lassnig - C. Bock - B. Strobl - M. Müller

P206 - ENGINEERING IL-12 TO ACHIEVE COMPLETE REMISSION IN ESTABLISHED, COLD TUMORS / A. Mansurov* - J. Ishihara - J. A. Hubbell

P207 - THE ERBB-STAT3 AXIS DRIVES TASMANIAN DEVIL FACIAL TUMOR DISEASE / B. Agerer* - L. Kosack - B. Wingelhofer - A. Popa - A. Orlova - B. Vilagos - P. Majek - K. Parapatics - A. Lercher - A. Ringler - J. Klughammer - M. Smyth - K. Khamina - H. Baazim - E. D. de Araujo - D. A. Rosa - J. Park - G. Tin - S. Ahmar - P. T. Gunning - C. Bock - H. V. Siddle - G. M. Woods - S. Kubicek - E. P. Murchison - K. L. Bennett - R. Moriggl - A. Bergthaler

P208 - ASPIRIN MODIFIES OBESITY-RELATED METABOLOMIC PROFILES AND SUPPRESSES BREAST CANCER CELL GROWTH / C.-C. Hsieh* - C.-H. Wang

P209 - GENETICALLY MEDIATED CELL AUTONOMOUS GP130 ACTIVATION AS THERAPEUTIC APPROACH IN PROSTATE CANCER / C. Sternberg* - M. Schlederer - R. Ziegler - T. Limberger - S. Högler - S. Tangermann - M. Al-Maarri - F. T. Wunderlich - S. Lagger - L. Kenner - S. Rose-John

P210 - STAT5, A POTENT DRIVER OF HEMATOPOIETIC CANCER / C. Wagner* - B. Maurer - H. Pham - H. Neubauer - R. Moriggl

P211 - STUDY OF THE EFFECTS OF IL-17/IL17R SIGNALING ON DIFFERENT MURINE TUMORS AND THEIR IMPACT ON TUMOR PROGRESSION / C. Rodriguez* - J. Tosello Boari - C. Araujo Furlan - F. Canale - S. Boccardo - S. Bossio - C. Beccaria - A. Gruppi - C. Montes - E. Acosta Rodriguez

37

P231 - ESTROGEN RECEPTORS PARTICIPATE IN CARCINOGENESIS SIGNALING PATHWAYS BY DIRECTLY REGULATING NOD-LIKE RECEPTORS / S. Song* - W. Fan

P232 - LOSS OF KMT2C METHYLTRANSFERASE ACTIVITY PROMOTES TUMORIGENESIS IN A MOUSE MODEL OF PROSTATE CANCER / T. Limberger* - M. Schlederer - S. Tangermann - S. Högler - C. Sternberg - Š. Pospíšilová - J. Oppelt - B. Tichý - H. Dolznig - S. Lagger - L. Kenner

P233 - THE ACTIVATING STAT5BN642H MUTATION IN IMMATURE T CELL NEOPLASIA / T. Suske* - H. Neubauer - H. Pham - B. Maurer - S. Tangermann - A. Orlova - T. Kolbe - A. Boersma - L. Kenner - T. Rülicke - R. Moriggl

P235 - ANALYSES OF CYTOKINES VALUES IN SERUM AS WELL AS IN ISOLATED CELLS FROM BONE MARROW OF PATIENTS WITH MULTIPLE MYELOMA / V. Jurisic* - K. Mirjacic - A. Vuletic - O. Markovic - M. Radojkovic - T. Rajic-Srdic

P236 - ANTITUMOR EFFICACY AND IMMUNE-MEDIATED MECHANISM OF THE HDAC INHIBITOR ENTINOSTAT IN THE POTENTIATION OF CYTOKINE-BASED IMMUNOTHERAPY / Y. Ozawa* - K. C. Hicks - K. M. Knudson - R. N. Donahue - J. Schlom - S. Gameiro

P236A - SLFN5 IS A TRANSCRIPTIONAL REPRESSOR OF TYPE I IFN-RESPONSES IN PANCREATIC CANCER / M. Fischietti* - F. Eckerdt - A. D. Arslan - G. T. Blyth - E. M. Beauchamp - D. Saleiro - W. Qiang - L. C. Platanias

P236B - THE JOINT EFFECT OF JAK INHIBITORS. CAN WE SELECTIVELY SUPPRESS ANTI- OR PROINFLAMMATORY RESPONSE? / K. Zakrzewska* - J. Walczak - K. Nienałtowski - P. Topolewski - A. Braniewska - T. Rygiel - M. Komorowski

P236C - IMPACT OF TRANSIENT CD4 DEPLETION ON CLONAL T CELL RESPONSES IN PATIENTS WITH GASTROINTESTINAL CANCER / S. Ueha* - H. Aoki - S. Shichino - H. Ogiwara - K. Shitara - M. Shimomura - T. Suzuki - T. Nakatsura - M. Yamashita - S. Kitano - S. Kuroda - M. Wakabayashi - S. Ito - T. Doi - K. Matsushima

P236D - DUSP6 DEFICIENCY RESTRAINS TCR-MEDIATED METABOLIC REPROGRAMMING WHICH CONFERS A SUPERIOR ANTI-TUMOR IMMUNITY / M-Y. Chen* - W-C. Hsu - Y-W. Su

P236E - NOVEL VARIANTS OF IL15-SUPERAGONIST IMMUNOCYTOKINES / I. Evdokimovskaia* - D. Zaripova - E. Kolosova - M. Grefenshtein - S. Ageev - A. Kononov - Y. Smirnova - A. Gordeev - I. Putintceva - S. Evdokimov - I. Ustiugov - A. Ulitin - V. Solovyev - R. Ivanov

P236G - SELECTIVE STAT3 INHIBITION IN THE TUMOUR MICROENVIRONMENT RESTRICTS GASTROINTESTINAL TUMOUR GROWTH / M. Alorro* - M. Eismann - F. Masson - M. Ernst

P236H - ROLE OF TFH CELL-DERIVED CYTOKINES IN ANTI-TUMOR IMMUNITY / R. Nurieva* - Z. Liu - Y-Z. Zhao - M. Divenko - A. Alekseev


CYTOKINES IN SKIN INFLAMMATORY DISEASESHighlighted posters will part of a poster tour

chaired by Sarah Gaffen (US)

P237 - IFNBETA IS A NOVEL EFFECTOR CYTOKINE IN RESOLVING INFLAMMATION AND SKIN FIBROSIS / A. Ariel* - S. K. Satyanarayanan - D. El Kebir - S. soboh - S. Butenko - M. Shekheri - T. Sheffer - J. Saadi - N. Peled - S. Assi - A. Othman - S. Schif-Zuck - Y. Feuermann - D. Barkan - N. Sher - J. G. Filep

P238 - THE LINEAR UBIQUITIN CHAIN BINDING DOMAIN NZF OF HOIL-1L REGULATES IMMUNE SIGNALING CASCADES / C. Gomez Diaz* - K. Schodl - L. Descz - A. Kavirayani - F. Ikeda

P239 - DOUBLE POSITIVE IL-17A+/ F+ T HELPER CELLS INDUCE INFLAMMATION AND RECRUITMENT NEUTROPHILS IN TYPE 1 REACTION OF LEPROSY /C. Saini* - R. Srivastava - V. Ramesh - A. Sharma

P240 - THE NOVEL CYTOKINE METRNL/IL-41 IS ELEVATED IN PSORIATIC ARTHRITIS SYNOVIUM AND INDUCED AT THE ENTHESIS / C. Bridgewood* - T. Russell - H. Weedon - T. Baboolal - A. Watad - R. Cuthbert - M. Wittmann - M. D. Wechalekar - D. McGonagle

P241 - DECIPHERING THE ROLE OF TYROSINE KINASE 2 (TYK2) DURING CONTACT HYPERSENSITIVITY / D. Acitores-Balboa* - C. Lassnig - A. Pölzl - B. Strobl - M. Müller

P242 - INTERLEUKIN-38 INTERACTS WITH DESTRIN/ACTIN-DEPOLYMERIZING FACTOR (ADF) IN HUMAN KERATINOCYTES / D. Talabot-Ayer - L. Mermoud - J. Borowczyk-Michalowska - W.-H. Boehncke - N. Brembilla - G. Palmer*

P243 - PLASTICITY OF SKIN-RESIDENT COMMENSAL-SPECIFIC T CELLS PROMOTES TISSUE REPAIR / I. Rao* - N. Bouladoux - Y. Belkaid

P244 - IL-36 SIGNALING IN KERATINOCYTES IS MANDATORY IN IMIQUIMOD-INDUCED PSORIASIS IN MICE / J. Goldstein* - E. Y. Bassoy - J. Palomo - A. Caruso - E. Rodriguez - C. Gabay

P245 - DIFFERENTIAL EFFECTS OF IL-17A AND IL-17E (IL-25) ON EPIDERMAL HOMEOSTASIS / J. Borowczyk-Michalowska* - C. Buerger - J. Drukala - D. Wnuk - V. Lang - W.-H. Boehncke - N. C. Brembilla

P246 - PROPIONIBACTERIUM ACNES INDUCED INNATE IMMUNE RESPONSE IN HUMAN MACROPHAGES / K. Fischer* - R. Tschismarov - T. Decker

P247 - CONSTITUTIVE OVEREXPRESSION OF INTERLEUKIN 38 AFFECTS HUMAN KERATINOCYTE FITNESS AND DIFFERENTIATION / L. Mermoud* - D. Talabot-Ayer - N. Brembilla - J. Borowczyk-Michalowska - G. Palmer

P248 - CHARACTERIZATION OF IL-24 EXPRESSION AND STUDY OF ITS ROLE IN CHRONIC SPONTANEOUS URTICARIA / M. Choteau* - L. de Montjoye - P. Cheou - E. Hendrickx - M. Baeck - L. Dumoutier

P249 - PLASMACYTOID DENDRITIC CELLS IN THE ENTHESIS ARE ABLE TO SECRET INTERFERON ALPHA / Q. Zhou* - R. Cuthbert - A. Watad - T. Russell - H. Rowe - A. Khan - P. Millner - P. Loughenbury - A. Rao - R. Dunsmuir - C. Bridgewood - D. McGonagle

38

P266 - IDENTIFICATION OF NOVEL SPECIES CONSERVED ANTIVIRAL NUCLEIC ACID-SENSING PROTEINS / F. L. Pennemann* - M. Habjan - A. Stukalov - C. Urban - T.-M. Lavacca - L. L. Andersen - L. Oubraham - C. Holze - E. Girardi - A. Mussabekova - G. Superti-Furga - C. Meignin - J.-L. Imler - A. Pichlmair

P267 - INDUCTION OF IL-1B SECRETION BY PATIENT-ISOLATED UROPATHOGENIC E.COLI IN BONE MARROW DERIVED MACROPHAGE / H. Shin*

P269 - THE EFFECTS OF DOCETAXEL IN COMBINATION WITH BRAZILIAN GREEN PROPOLIS TOWARDS BREAST CANCER (MCF-7) CELLS AND ON CYTOKINE PRODUCTION BY HUMAN MONOCYTES / J. M. Sforcin* - E. O. Cardoso - K. B. Santiago - B. J. Conti - F. L. Conte - K. I. Tasca - J. K. Bastos

P270 - THE INFLUENCE OF ARGININE AVAILABILITY ON RANKL MEDIATED OSTEOCLASTOGENESIS /J. S. Brunner* - L. Vulliard - M. Hoffmann - V. Saferding - A. Vogel - A. Lercher - B. Niederreiter - P. Cheng - G. Schabbauer - S. Blüml

P271 - THE ROLE OF MITOCHONDRIAL SARM IN DEFINING CELL FATE AFTER INFLAMMASOME ACTIVATION / K. A. Shanahan* - M. Carty - A. G. Bowie

P272 - IMBALANCED MYELOPOIESIS BY TREATMENT OF ANTI-CANCER DRUGS AGGRAVATES TUBERCULOSIS PROGRESSION / K. W. Kwon* - T. G. Kang - S.-J. Ha - S. J. Shin

P273 - CNA ACTIVATION CAN IMPROVE NEONATAL INNATE IMMUNE RESPONSES TO ALUM AND OTHER POTENTIAL VACCINE ADJUVANTS / K. Brennan* - S. Craven - E. J. Molloy - P. T. Walsh - F. McAuliffe - S. L. Doyle

P274 - CHARACTERIZATION OF PURINERGIC RECEPTOR REGULATION OF INNATE IMMUNE RESPONSES THROUGH SENSING OF NUCLEOTIDE BASED DAMPS / L. L. Andersen* - C. Urban - B. Laudenbach - C. Heuser - P. Knolle - V. Hornung - C. Zielinski - A. Pichlmair

P275 - TYPE I INTERFERON SIGNALING PLAYS A PROMINENT ROLE IN FOLLICULAR RESISTANCE TO MCMV INFECTION IN THE OVARIES / M. Mazor* - J. Tomac - V. Juranić Lisnić - D. Kveštak - B. Lisnić - J. Boneta - M. Brinkmann - L. Dolken - A. Krmpotić - S. Jonjić

P278 - STAT1 ISOFORMS DIFFERENTIALLY REGULATE NK CELL MATURATION AND FUNCTIONALITY / K. Meissl - N. Simonovic* - L. Amenitsch - A. Witalisz-Siepracka - K. Klein - C. Lassnig - T. Kolbe - V. Sexl - M. Müller - B. Strobl

P279 - DIETARY FIBER-INDUCED MICROBIAL SHORT CHAIN FATTY ACIDS SUPPRESS ILC2-DEPENDENT AIRWAY INFLAMMATION / P. Soroosh* on behalf of Gavin Lewis and Omid Akbari

P280 - INTERFERON LAMBDA 4 CAUSES ENDOPLASMIC RETICULUM STRESS AND SUPPRESSES RIBOSOMAL PROTEIN SYNTHESIS IN LIVER-DERIVED ORGANOIDS / Q. Chen* - M. Coto - A. Suslov - I. Fofana - S. Wieland - M. Heim


P250 - T CELL DELETION OF MYD88 CONNECTS IL-17 AND IKBZ TO RAS ONCOGENESIS / R. Salcedo* - C. Cataisson - G. Trinchieri - S. H. Yuspa

P251 - IL-17F AND IL-17A EQUALLY CONTRIBUTE TO THE PATHOGENESIS OF EXPERIMENTAL EPIDERMOLYSIS BULLOSA ACQUISITA / S. Jukic* - F. Deng - I. Prinz - B. Becher - A. Waisman - E. Schmidt - F. Petersen - C. Hölscher

P252 - TYK2 SIGNALING IN IMMUNITY AGAINST CANDIDA ALBICANS SKIN INFECTIONS / S. Miranda* - N. Simonović - C. Lassnig - A. Pölzl - K. Kuchler - M. Müller - B. Strobl

P253 - SIGNIFICANT INTERACTION BETWEEN PRE-IL-1A AND PRE-IL-33 CONTRIBUTES TO TISSUE FIBROSIS IN SYSTEMIC SCLEROSIS / Y. Kawaguchi* - T. Higuchi - K. Takagi - M. Harigai

P254 - EFFECTS OF VACCINIA VIRUS-DRIVEN EXPRESSION OF INTERFERON REGULATORY FACTOR 3 ON PROTECTIVE IMMUNITY AGAINST LETHAL POXVIRAL INFECTION AND ON CYTOKINES EXPRESSED IN SKIN OF ATOPIC NC/NGA AND CONTROL BALB/C MICE / Z. Melkova* - V. Hajkova - H. Pilna

P255 - TLR3 ACTIVATION REDUCES ANTIVIRAL RESPONSE TRIGGERED BY RIG-LIKE RECEPTORS DURING ZIKA VIRUS INFECTION / A. Plociennikowska* - J. Frankish - T. Moraes - M. Binder - R. Bartenschlager

P256 - IFNAR1 SIGNALING BREAKS THE HEPATIC UREA CYCLE TO REGULATE ADAPTIVE IMMUNITY / A. Lercher* - A. Bhattacharya - A. Popa - M. Caldera - M. F. Schlapansky - H. Baazim - P. Majek - J. Brunner - L. J. Kosack - D. Vitko - T. Pinter - B. Gürtl - D. Reil - U. Kalinke - K. Bennett - J. Menche - P. Cheng - G. Schabbauer - M. Trauner - K. Klavins - A. Bergthaler

INNATE IMMUNITYHighlighted posters will part of a poster tour

chaired by Leo Joosten (NL)

P257 - IFN ALPHA AND IFN GAMMA MUTUALLY EXCLUSIVELY ACTIVATE ISGF3 AND GAF TO COLLABORATE WITH TLR4-INDUCED P65 AND ENHANCE PRO-INFLAMMATORY TRANSCRIPTION / A. Piaszyk-Borychowska* - H. A. R. Bluyssen

P259 - SELECTIVE AUTOPHAGIC DEGRADATION OF MDA5 LIMITS PRODUCTION OF TYPE I INTERFERONS / B. Hu* - Y. Zhang - J. Lei - Y. Li - C. XU - J. Gu - J. Liu - L. Du - J. Zhou

P262 - ROLE OF IRF9 IN INNATE IMMUNITY AGAINST LISTERIA MONOCYTOGENES / D. Demiroz* - A. Lercher - A. Bergthaler - T. Decker

P264 - ENGAGEMENT OF FAS DIFFERENTIALLY REGULATES THE PRODUCTION OF LPS-INDUCED PRO-INFLAMMATORY CYTOKINES AND TYPE I INTERFERONS / E. Brint* - K. brennan - S. Doyle - A. Houston

P265 - EXAMINING THE DYNAMICS OF TYPE I INTERFERON-MEDIATED JAK-STAT SIGNALING WITHIN THE INNATE IMMUNE RESPONSE / E. Mesev* - B. Heller - J. Toettcher - A. Ploss

39

P281 - PATHOBIOLOGY OF WEST NILE VIRUS INFECTION IN THE COLLABORATIVE CROSS MOUSE MODEL / R. C. Ireton* - A. Sekine - S. Thomas - P. Treuting - R. Green - K. Voss - M. Mooney - S. McWeeney - M. Gale Jr.

P283 - IMMUNE RESPONSE PROFILES OF CALVES FOLLOWING VACCINATION WITH BOVINE RESPIRATORY DISEASE COMPLEX / S.-M. Lee* - A. R. Prasad - S. Salam - Y. J. Kim - S. Ha

P285 - RECOGNITION OF DENGUE VIRUS INFECTION BY TLR2/MYD88 SIGNAL FACILITATES TH2-BIASED ANTIBODY-DEPENDENT ENHANCEMENT / S. K. Eo* - J. Y. Choi - E. Uyangaa - S. O. Park

P286 - MID50, A NOVEL METHOD TO QUANTIFY TYPE I IFN / S. Rius Rocabert* - J. L. Presa - S. Esteban-Rubio - A. Ayuso-Sacido - E. Nistal-Villan

P287 - ADIPONECTIN DEFICIENCY PROMOTES CHRONIC INFLAMMATION DURING AGING THROUGH REGULATION OF INNATE IMMUNE CELLS AND MESENCHYMAL STEM CELLS IN BONE MARROW / S. Han* - Y. Yang

P288 - GENETIC ADAPTATION PROTECTS TIBETANS AGAINST INFLAMMATORY COMPLICATIONS / S. bhattacharya* - N. Shrimali - G. Mohammad - P. Koul - J. T. Prchal - P. Guchhait

P290 - THE ROLE OF SELECTIVE AUTOPHAGY IN INTRACELLULAR INFECTIOUS BURSAL DISEASE VIRUS (IBDV) CLEARANCE / Y. Li* - C. XU - J. Lei - B. Hu

P290A - SAA1 REVISITED: SPECTRUM OF LEUKOCYTE-ACTIVATING PROPERTIES OF HOMOGENEOUS SAA1 / S. Struyf* - S. A. Salama - M. De Bondt - M. De Buck - N. Berghmans - M. Gouwy - J. Van Damme

P290B - LACTATE REGULATES BONE MARROW NEUTROPHIL MOBILIZATION VIA ENDOTHELIAL GPR81 SIGNALING AND CXCL1/CXCL2 SECRETION / E. Khatib-Massalha* - S. Bhattacharya - H. Massalha - K. Golan - O. Kollet - A. Kumari - F. Avemaria - T. Itkin - S. Gur-Cohen - S. Offermanns - R. Alon - A. Ariel - T. Lapidot

P290C - SKIN INNATE ANTIMICROBIAL IMMUNITY IS REGULATED BY IFN-DEPENDENT AND IFN-INDEPENDENT MECHANISMS AND PROTECTS AGAINST FLAVIVIRUS INFECTION / A. S. Macleod* - J. Kwock - C. Handfield

P290D - RNASE L CONTRIBUTES TO THE FUNCTION OF MACROPHAGES / A. Zhou* - R. Wei - C. Zeng - G. Chen

P290E - TREM2-INDUCED TYROSINE HYDROXYLASE ALLEVIATES THE PROGRESSION OF PARKINSON’S DISEASE / S. Kim* - S-M. Kim - H-R. Choi - H-S. Kang

P290F - CHARACTERIZATION OF TWO GAIN-OF-FUNCTION STAT1 MUTANTS RESULTING IN PREMATURE CYTOKINE-INDUCED NUCLEAR ACCUMULATION / T. Meyer* - J. Petersen - P. Menon - S. Mumtaz - A. Ivetic

P290H - ASC-MUTATED JAPANESE MEDAKA ORYZIAS LATIPES BY CRISPR-CAS9 SYSTEM OBTAINS RESISTANCE TO INFECTION OF EDWARDSIELLA PISCICIDA / J-I. Hikima* - N. Morimoto - Y. Okamura - T. Kono - M. Sakai

P290I - HEPATITIS C VIRUS INFECTION IS INHIBITED BY A NON-CANONICAL ANTIVIRAL SIGNALING PATHWAY TARGETED BY NS3-NS4A / C. Vazquez* - C. Y. Tan - S. Horner


with PBL’s Assay Soluti ons!

PBL Assay Science, your trusted source for interferon ELISAs, proteins, antibodies, and assay services is proud to be a sponsor for the Cytokines 2019 Conference.

We invite you to visit us in the Conference Exhibit Hall and poster presentation (no. P204A) to discover how our IFN Alpha All-Subtype ELISA kits and other

offerings can help you in your research.

Experimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyExperimental SymphonyCONDUCT YOUR

Hit-ti ng all the IFN Al-pha Sub-type Notes

α14

α7

α1

α5

α2a

α4a α8

α10

α16

α17

α21α6

41

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Please visit: www.abcam.com

Abcam

BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Our portfolio includes research tools for cancer, immunology, neuroscience, cell biology, and stem cells. We offer 700+ bioassay-validated recombinant cytokines and growth factors, and LEGENDplexâ„¢ bead-based immunoassays to quantify multiple soluble analytes simultaneously using a flow cytometer. BioLegend operates under an ISO 13485:2016 certified quality management system.

BioLegend

AYOXXA Biosystems GmbH is an international life science company with headquarters in Cologne (Germany). With LUNARIS(TM), its proprietary beads-on-a-chip multiplexing platform the Company is paving the way for translating knowledge generated in a laboratory environment through clinical studies in support of basic biology and drug development. LUNARIS(TM) enables fully scalable quantitative validation of biomarkers in minute amounts of biological samples. AYOXXA is commercializing a growing portfolio of standardized ready-to-use biomarker assays, with a focus on the biology of inflammation and immune response.

AYOXXA Biosystems GmbH

Bio-Techne® unites the trusted brands: R&D Systems®, Novus Biologicals®, Tocris®, ProteinSimple® and Advanced Cell Diagnostics® (ACD). Over 50,000 products: Proteins and Antibodies - Validated antibodies in many formats. Small molecules - High quality, high purity, fully annotated novel small molecules/peptides. Protein analysis platforms - Simple PlexTM, Simple WesternTM, Single-Cell Westerns and iCETM platforms. ELISAs and Luminex® - Quantikine® and DuoSet® ELISAs, bead-based multiplex assays and Luminex® instruments. RNA ISH - Advanced in situ hybridization (ISH) assay RNAscope® Technology to identify target genes in any species, in any tissue.

Bio-TechneEmail: [email protected]: www.abcam.comPhone: +1 617 577 42 00

Email: [email protected]: www.ayoxxa.comPhone: +49 221 222 52 90

Email: [email protected]: www.biolegend.comPhone: +1 858 455 95 88

Email: [email protected]: www.bio-techne.comPhone: +44 123 552 94 49

Bon Opus Biosciences is an NJ-based Contract Research Organization. Our areas of expertise include gene synthesis, custom protein expression, and custom antibody production. All proteins have activity and purity data testing performed and reported. In addition to our vast recombinant protein catalog featuring up to 2,000 protein products, we also carry a comprehensive catalog of over 3,000 primary antibodies, both monoclonal and polyclonal. Bon Opus has built several service programs that are specifically designed to support the development of targeted therapeutics - in particular, antigen production and monoclonal antibodies.

Bon Opus BiosciencesEmail: [email protected]: www.bonopusbio.comPhone: +1 800 943 63 96

Company Profiles

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunology and fibrosis. Through the Bristol-Myers Squibb Foundation, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.

Bristol-Myers SquibbWebsite: www.bms.com

42

Company Profiles

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com

Eli Lilly Ges.m.b.HEmail: [email protected]: www.lilly.atPhone: +43 1 711 78-0 (office)

EFIS unites 35 European national immunological societies and their 14,000 individual members, pursuing its mission to advance education, training, research and collaboration in immunology and related fields. With its partner journal, the European Journal of Immunology, EFIS offers financial support to the organizers of high-caliber immunology-related international meetings, workshops and schools to enhance interaction between young scientists and established immunologists, funding the participation costs of junior researchers who would otherwise be unable to attend quality immunology-themed events.

European Federation of Immunological Societies (EFIS)

Leading the way in advancing science, technology and health. Elsevier helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Combining content with technology, supported by operational efficiency, Elsevier turns information into actionable knowledge. Elsevier empowers knowledge which empowers those who use it.

ElsevierEmail: [email protected]: www.elsevier.com

Email: [email protected]: www.efis.org

At Janssen, we are relentlessly dissatisfied with the status quo since, despite significant advances, there is still immense unmet need among those living with immune-mediated disease. Our vision is a future where the millions of people living with immune-mediated disease experience a lifetime of vibrant health. To make that future a reality, we operate at the intersection of unmet need, deep disease insights and novel pathway science, persistently pushing the boundaries of science and creativity to deliver transformational approaches that redefine the treatment of immune-mediated diseases.

Janssen ImmunologyEmail: [email protected]: www.janssen.com/immunology

Mary Ann Liebert, Inc.

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Journal of Interferon & Cytokine Research, OMICS: A Journal of Integrative Biology, Journal of Computational Biology, and Zebrafish. These publications play an active and vital role in advancing critical research and facilitating collaboration throughout the world in academia, industry, and government, and are also highly respected resources for legislators, policy makers, and educators.

Email: [email protected]: www.liebertpub.com

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializesmedicines to treat patients with serious or life-threatening medical conditions. We are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

Genentech, Inc.

44

Company Profiles

Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar’s proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Further information about the company and its drug development programs and capabilities may be found online at nektar.com.

Nektar TherapeuticsWebsite: www.nektar.com

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 thousand people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

NovartisWebsite: www.novartis.com

PBL Assay Science

PBL Assay Science works hand in hand with researchers to help solve difficult assay development and protein quantification problems. Known as a trusted source for high quality, high sensitivity ELISAs as well as interferon proteins and antibodies for more than 30 years, we provide cytokine assay solutions that include low-picogram IFN ELISA kits, unique cytokine multiplex ELISA kits, high quality protein and antibody reagents, and assay services to scientists around the world. From accurate detection of human IFN-beta in autoimmune disease sera to sub-picogram cytokine assays, our products and services are designed to provide you with highly reproductible results.

Email: [email protected]: www.pblassaysci.com

Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

Website: www.pfizer.com

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to today’s approach to healthcare by giving researchers the ability to closely examine the continuum from health to disease. Simoa technology is designed to enable earlier disease detection and enhanced treatment methods to improve the quality of life and longevity for generations to come. Simoa is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation, and more.

Quanterix Corporation Email: [email protected]: www.quanterix.comPhone: +1 617 301 94 00

Meso Scale Discovery (MSD®) is a leader in high performance, multiplex-enabled biomarker assays for cytokines, toxicology, neurodegeneration and metabolic disease research, used by leading biopharmaceutical and academic researchers in human and animal model studies. MSD™s proprietary electrochemiluminescence (ECL) platform delivers exceptional sensitivity, wide dynamic range and rapid turnaround. For more information, visit www.mesoscale.com.

Meso Scale DiscoverEmail: [email protected]: www.mesoscale.comPhone: +1 240 314 26 00

45

Company Profiles

The Society for Leukocyte Biology (SLB) is a community of like-minded researchers and clinicians. Emphasizing supporting members, SLB provides numerous opportunities to present and publish at conferences and through the Journal of Leukocyte Biology. Numerous committees include opportunities to gain experience and lead the direction of the organization. SLB organizes workshops providing professional development training. An extensive awards program supports members from many backgrounds. Mentoring support is included to foster the growth of trainees. SLB provides these services while growing globally and expanding opportunities for member to member collaboration.

Society & Journal for Leukocyte BiologyEmail: [email protected]: www.leukocytebiology.orgPhone: +30 12 04 22 33

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving.

Swedish Orphan Biovitrum GmbHEmail: [email protected]: www.sobi-deutschland.dePhone: +49 895 506 67 60

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our premier brands Thermo Scientific, Applied Biosystems, Invitrogen and Gibco brands we offer an unmatched combination of innovative technologies to help our customers accelerate life science research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity.

Thermo Fisher ScientificWebsite: www.thermofisher.com

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For additionalinformation about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

RegeneronWebsite: www.regeneron.com

We’re in the business of patients, not patience.

The

imag

e d

epic

ted

co

nta

ins

mo

del

s an

d is

bei

ng

used

for

illus

trat

ive

pur

po

ses

on

ly.

© J

anss

en R

esea

rch

& D

evel

op

men

t, L

LC 2

019

We like to think it’s our commitment to bold breakthrough innovations,along with a healthy dose of impatience, that has helped us develop andintroduce five medicines for immune-mediated diseases. Another waywe are creating a future where disease is a thing of the past. Learn more at www.janssen.com.

We’re hiring! Learn how to join our team at www.careers.jnj.com

47

Layout of Venue & Exhibition Area

FESTSAAL

PO

STER

AR

EA

POSTER AREAPOSTER AREA

COMPANY NAMES & BOOTH NUMBERS

Leukocyte Biology

Meso Scale Discovery

PBL Assay Science

Quanterix

Swedish Orphan Biovitrum GmbH

Thermo Fischer Scientifi c

B

5

6

2

8

3

ABCAM

AYOXXA Biosystems GmbH

Bio Techne

BioLegend

Bon Opus Biosciences

International Cytokine & Interferon Society

Janssen

10

11

1

4

7

A

9

48

Acknowledgements

PLATINUM SPONSORS

GOLD SPONSORS

SILVER SPONSORS

OTHER SPONSORS, EXHIBITORS & MEDIA PARTNERS

Partnering to furtherunderstand the basic

research needs of disease

Cooperating with the rheumatology community tobetter understand remission

Introducing innovation and technology into our clinical

trial designs

Supporting medicaleducation initiatives

Collaborating withnational registries

Initiating non-interventional

studies

NovartisSupporting therheumatology communityto improve patients’ lives

GLDEIM/AIN457A/1253 Date of preparation: October 2019. Date of expiry: October 2020

Copyright © 2019 Novartis Pharma AG Reimagining Medicine

50

Notes

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laborin our laboratories.

SCIENCE AS LIMITLESSAS OUR CURIOUSITY

R E G E N E R O N . C O M @ R E G E N E R O N

A NEW PATHWAY THAT COULD HELP TREAT IMMUNE-MEDIATED DISEASES?

Bristol-Myers Squibb is committed toresearching and developing innovativenew treatments that can help betteraddress unmet patient needs.With an increased understanding ofimmune-mediated and infl ammatorypathways, BMS is identifying novelnew targets that could potentiallyevolve the way we help patients.

Pathbreaking science.

Making every day better.

©2019 Bristol-Myers Squibb Company. IMSAT19NP01678-01

Hofburg Conference Center, Vienna, Austria · MOBILE APPLICATION Get all information you need at...

Documents

Transcript of Hofburg Conference Center, Vienna, Austria · MOBILE APPLICATION Get all information you need at...